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ABSTRACT 
Computational simulations to study the kinetics of drug efflux via multidrug resistant 
membrane proteins expressed in confluent cell monolayers: A critical evaluation of 
different models employed, data fitting techniques and global optimization strategies 
 
Deep Agnani 
Advisor: Dr. Joe Bentz 
 
 
 
 
Computational models have often been employed to understand the kinetics of drug 
efflux via membrane proteins expressed in relevant systems. One such membrane protein 
extensively studied is P-glycoprotein (P-gp), a multidrug resistance protein expressed in 
the apical surface of epithelial cells lining several organs and tissues. Several models 
have been employed to understand the kinetics of drug efflux via P-gp. One such model 
is the minimal mass action model which is capable of determining the elementary kinetic 
parameters thereby providing a better understanding of the structure–function 
relationship of P-gp. One of the limitations of this model is that it gives a small range of 
possible values for each parameter, rather than a lone vector of fits. One aspect of this 
study is to determine the basis for the range. We find that the “range” cannot be attributed 
to inherent experimental error. Rather it can be attributed to the global optimization 
technique of the model, i.e. determining all the parameters simultaneously. The 
Michaelis-Menten model is also employed to study P-gp kinetics. This model allows us 
to determine the maximal rate of drug efflux (Vmax) and the Michaelis-Menten constant 
(Km). This model was originally designed for enzymes which catalyze reactions in 
aqueous environments. It is unclear if it is suitable to apply this model to membrane 
 xi
proteins such as P-gp, which directly pick substrate from the membrane. Bentz et al. 
(2005) using data generated by simulations employing the minimal mass action kinetic 
model, showed that experimentally determined Vmax values correlates reasonably well 
with the molecular Vmax, as determined by the elementary rate parameters. However, they 
found no correlation between the molecular and experimental Km values, even if the data 
had no error. Recently, Sun and Pang (2008), using data generated by simulations 
employing the steady state Michaelis-Menten model, obtained the exact opposite result. 
Our second objective was to compare and contrast the two computational models in their 
abilities to determine the kinetic parameters and to examine the possible reason for the 
discrepancies in correlations obtained by the same. We find that the original results of 
Bentz et al. (2005) hold, irrespective of the model employed. This is subjected to the fact 
that appropriate substrate concentrations (those capable of saturating at least 70% of P-gp 
present) are used. We know that P-gp is expressed in the apical membrane of epithelial 
cells, which are composed of microvilli. Microvilli are dynamic structures. Their 
expression can be altered thereby altering cellular surface area. This in turn could alter P-
gp expression, besides affecting passive transport. The third aspect of my study is to 
understand how the changing microvilli morphology affects efflux of compounds. We 
discover that as long as the height of the microvilli is lesser than the distance between 
two adjacent microvilli, the number of molecules escaping per unit area of the membrane 
remains constant. If the height becomes greater than the distance between microvilli, the 
number of escapes per unit area falls considerably. 
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PART I – INTRODUCTION 
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1. Modeling the Kinetics of Substrate Transport in Biological Systems 
 
Systems biology is a field that strives to study biological systems in silico. It is often 
employed to study the interactions between components of a system and how these 
interactions can give rise to a function in the system.  
The systems biology approach involves the development of a dynamic model using 
mathematical equations that appropriately describe the process under study. One of the 
primary uses of systems biology lies in understanding certain aspects of a system/process 
by getting rid of noise and biological variations. It may also be used to predict the 
behavior of a system under a known set of controls. Of course, certain 
assumptions/simplifications are made, without which it would be impossible to perform 
such a study. 
One of the areas where systems biology finds its roots is the quantitative modeling of the 
kinetics of transport of substances by membrane proteins. Earliest works in this area dates 
back to the 1950s (Sheppard and Martin, 1950; Blaxter et al., 1956; Robertson et al., 
1957). Its importance lies in the fact that the transport of a substance across the epithelial 
layer of cells lining the lumen of an organ can be correlated to its availability within the 
organ itself. Initially, simple models were employed to elucidate the involvement of a 
protein in the transport process. With the advent of faster computers, it became possible 
to design and explore more complex models towards this purpose. Today, studying the 
involvement of membrane transporters in the Absorption, Distribution, Metabolism, and 
Excretion (ADME) of drugs using such models is a common undertaking in the 
pharmaceutical industry. 
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It is important to remember that it is impossible to model/simulate every aspect of a 
biological process since biological systems are very complex. Thus the development of 
any model has simple assumptions/constraints built into it. What is imperative to 
remember when applying such assumptions/constraints is that they are biologically 
relevant or else the biological significance of the model is lost. Since models are 
generally based on experiments conducted in vitro, it is also important to understand the 
limitations of a model to extrapolate its findings to in vivo conditions. 
This work aims to critically evaluate different models, data fitting techniques and global 
optimization strategies employed to study the kinetics of drug efflux by P-glycoprotein 
expressed in a confluent monolayer of Madin Darby Canine Kidney (MDCK II – hMDR1) 
cells. I shall thoroughly assess a newly adopted minimal mass action kinetic model that is 
being employed towards this purpose. I shall explain the advantage of using this model 
over currently existing models (such as the steady state Michaelis-Menten model). I shall 
identify and explain the limitations of this model. A better understanding of the basis of 
the limitations allows us to effectively extrapolate the findings of this model in vivo. 
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2. ABC Proteins, Diseases and Multidrug Resistance 
 
Before we embark towards understanding and evaluating the various mathematical 
models used to study the kinetics of drug efflux by membrane transporters, we need to 
understand the importance of the transporters involved in the process, the primary 
question being, why are we interested in studying these transporters? In this chapter, I 
shall provide a literary overview on the ATP Binding Cassette (ABC) family of proteins, 
a family whose role in transport has been extensively studied. In the next chapter, I shall 
present a summary on the work done, so far, of P-glycoprotein, our protein of interest. 
 
Transport proteins constitute 15% to 30% of membrane proteins in a cell. They are 
critical in the movement of various ions, solutes and nutrients across cell membrane. It is 
believed that almost 60% of the energy consumption is devoted to transport processes in 
mammalian cells (Sauna and Ambudkar, 2007). One of the largest and most diverse 
family of transport proteins is the ATP-binding cassette (ABC) family (Dean et al., 2001; 
Gottesman and Ambudkar, 2001; Dean and Annilo, 2005). 
  
2.1 Structure of ABCs 
2.1.1 General structure of ABCs 
A functional ABC protein generally consists of two transmembrane (TM) domains and 2 
ATP binding domains, also called nucleotide binding domains (NBDs) or nucleotide 
binding folds (NBFs). The NBDs are located in the cytoplasm and transfer energy to 
transport substrates across membranes (Dean et al., 2001). In eukaryotes, ABCs genes 
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can encode both TMs and NBDs or occur as “half transporters”. However, “half 
transporters” must form homodimers or heterodimers to constitute a functional unit 
(Hyde et al., 1990). The TM domains comprise of 6-11 α-helices which provide substrate 
specificity to the transporter (Dean et al., 2001) 
 
2.1.2 The ATP-binding domain: A signature domain of all ABCs 
A transporter is classified as an ABC transporter based on the sequence and organization 
of its ATP-binding domains, also known as nucleotide-binding domains (NBDs). NBDs 
contain a Walker A motif (Gly –X-X-Gly-X-Gly-Lys-Thr/Ser and a Walker B (Arg/Lys-
X-X-X-Gly-X-X-X-Leu-hydrophobic-hydrophobic-hydrophobic-Asp) (Walker et al., 
1982). The Walker A motif is a glycine-rich loop. It interacts with the phosphate groups 
of the bound nucleotide and an Mg2+ ion (which is coordinated to the side chain of 
residue 8 of the motif), which coordinates the β- and γ-phosphates (Smith and Rayment, 
1996). The Walker B motif has been shown to be involved in the binding of γ-phosphate 
(Smith and Rayment, 1996). The Walker A and B motifs are separated by ~90-120 amino 
acids (Dean et al., 2001). A linker (C motif) with the sequence Lys-Ser-Gly-Gly-Gln is 
found just upstream of the B motif (Dean and Annilo, 2005). The NBDs also contain the 
D-loop, H-loop and Q-loop. The presence of a highly conserved A loop, consisting of an 
aromatic residue 25 amino acids upstream of the Walker A motif (Ambudkar et al., 2006; 
Kim et al., 2006) has been shown. It is believed that the ATP is sandwiched between the 
Walker A, Walker B, Q-loop, and H-loop of one NBD and the D-loop and C motif of the 
opposing NBD. It has been shown that the formation of this ATP sandwich is important 
for transport (Ambudkar et al., 2006). 
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2.2 ABC transporters and disease 
A large number of genes encode for ABC transporters. Single cell eukaryotes have 16 – 
32 ABC genes while multicellular animal species have 47 – 68 (Dean and Annilo, 2005)  
There are 48 ABC genes in the human genome divided into 7 ABC subfamilies 
designated A-G, based on amino acid sequence similarity and phylogeny (Dean et al., 
2001). Of these, 17 have been implicated in diseases (Gottesman and Ambudkar, 2001). 
Mutations of ABC transporters have been linked to several complex diseases or 
Mendelian disorders including (but not limited to) cystic fibrosis/ pancreatitis/ 
bronchiectasis (defects in ABCC7), Tangiers disease (mutations in ABCA1), Dubin-
Johnson syndrome (mutations in ABCC2) and age related macular degradation/ 
Stratgardt disease (mutations in ABCA4). These have been eloquently summarized in a 
review by Dean et al. (2001). 
 
2.3 ABC transporters and multidrug resistance 
Multidrug resistance (MDR) in a phenomenon by which cells develop a resistance to 
several drugs that appear to be structurally and functionally unrelated. Multidrug 
resistance in bacteria has been attributed to problems in combating gonorrhea, pneumonia 
and tuberculosis (Ouellette et al., 2001). Multidrug resistant strains of Enterococcus 
faecalis, Mycobacterium tuberculosis, and, Pseudomonas aeruginosa are capable of 
causing life threatening illnesses (Levy, 1998). Besides these diseases, the emergence of 
multidrug resistant cells serves as a major obstacle in the treatment of malaria, HIV and 
cancer. About 40% of all human cancers are estimated to develop multidrug resistance, 
thus rendering chemotherapy ineffective (Sauna and Ambudkar, 2007). Multidrug 
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resistance in humans has been attributed to the overexpression of ABCB1 (also known as 
MDR1, PGY1 or P-glycoprotein), ABCC1 (also known as MRP1) and ABCG2 (also 
known as ABCP, MXR1 or BCRP) (Dean et al., 2001). 
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3. P-glycoprotein: A Brief Summary of the Work Done Over the Years 
 
P-glycoprotein (P-gp) was one of the first members of the ABC transporter superfamily 
to be studied. It invoked interest because of its link to MDR in mammalian cells and 
human cancers P-gp genes from human, mouse and Chinese hamster have been cloned 
and sequenced (Sharom, 2007).  
A 170,000 Dalton protein was first discovered to endow Chinese hamster ovary cells with 
resistance to colchicine. It was found to be absent in wild type cells. This protein was 
shown to be a cell surface glycoprotein. It was named P-glycoprotein as cells expressing 
this protein showed altered permeability to colchicine, when compared to wild type cells 
(Juliano and Ling, 1976). Later, amplified genomic fragments were isolated from these 
cells (Roninson et al., 1984) and using these genomic fragments, the MDR1 gene product, 
that encodes for human P- gp was later identified from multidrug resistant KB cells 
(Roninson et al., 1986).  
In this thesis the term P-gp is used to refer to the ABCB1 gene product (i.e., the product 
of the human MDR1 gene). I will restrict myself to talking about this transporter, unless 
otherwise indicated. Now and then, I may divulge information gathered on homologues 
of P-gp isolated and studied from other organisms, to give a better understanding on the 
structure and function of P-gp. 
P-gp is comprised of 1280 amino acids. The MDR1 gene that encodes this protein is 
located on chromosome 7 and consists of 28 exons. The protein has two homologous 
halves, each containing six transmembrane domains and one ATP-binding site (Fromm, 
2002).  
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3.1 Tissue distribution of P-gp 
P-gp is expressed in low levels in most tissues but is found in high amounts at the apical 
surface of epithelial cells that line the colon, small intestine, adrenal gland, pancreatic and 
bile ductules, and the kidney proximal tubule (Sharom, 2007). P-gp has also been located 
at the endothelial tissue of the blood-brain barrier (Beaulieu et al., 1997), the blood-testis 
barrier (Melaine et al., 2002), and the blood-mammary tissue barrier (Edwards et al., 
2005). It is expressed in high numbers on the luminal surface of excretory cells in 
pregnant endometrium (Arceci et al., 1988) and the placenta (Gil et al., 2005). P-gp is 
also expressed in several leukocyte lineages (Klimecki et al., 1994). The general 
physiological function of P-gp appears to be the extrusion of xenobiotics from these cells. 
 
3.2 The structure of P-gp 
No high resolution x-ray structure of P-gp is available. However, extensive understanding 
has been gained on the structure and, to some extent, the function of P-gp by studying the 
vanadate-trapped complex of P-gp and cysteine scanning mutagenesis (Loo and Clarke, 
1993; Loo and Clarke, 1999; Loo and Clarke, 2000; Loo and Clarke, 2001; Loo et al., 
2003; Loo et al., 2005; Loo and Clarke, 2005; Loo and Clarke, 2005a). 
Each of the 12 transmembrane (TM) domains in P-gp has 21 amino acids. They are 
predicted to exist as α-helices separated by extracellular hydrophilic loops. Amongst 
these TM domains, TM6 and TM12 are known to be associated with the NBDs and are 
believed to be particularly important to transport (Loo and Clarke, 1999). Details of 
interactions of the various domains have been elucidated in the section “The drug binding 
site of P-gp”. 
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The structure of mouse P-gp embedded in a lipid bilayer has been studied by electron 
microscopy and image analysis to a resolution of 22 Å (Lee et al., 2002). It is important 
to note that mouse P-gp has very high (87%) sequence homology to human P-gp (Aller et 
al., 2009). It has been shown to have immunogenic homology to human P-gp as well 
(Kartner et al., 1983). Thus observations made on mouse P-gp may be extended to human 
P-gp. 
The structure of P-gp isolated from Chinese hamster ovary (CHO) cells have also been 
well studied. These have also been shown to have immunogenic homology to human P-
gp (Kartner et al., 1983). An initial low resolution (2.5nm) electron microscopy and 
single particle image analysis of both detergent-solubilized and lipid reconstituted 
hamster P-gp indicated that the protein has a large central pore about 5nm in diameter 
which is closed at the cytoplasmic face of the membrane, forming an aqueous chamber 
within the membrane. The presence of an opening from this chamber to the lipid phase 
was reported. It was speculated that drug molecules may enter the pore through this 
opening (Rosenberg et al., 1997). Later, the three dimensional structure of the protein in 
the presence and absence of nucleotide, at a resolution of 2nm was determined by 
electron crystallography of negatively stained crystals (Rosenberg et al., 2003; Rosenberg 
et al., 2005). This study indicates that when the nucleotide binds, the TMs reorganize into 
3 compact structures, each 2 – 3 nm in diameter and 5 – 6 nm in depth. This opens up the 
central pore along its entire length which in turn facilitates the movement of drug 
molecules from the lipid bilayer to the aqueous pore. 
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3.3 The drug binding site of P-gp 
P-gp is known to transport only those molecules that partition into the lipid bilayer 
(Shapiro and Ling, 1994; Seelig and Landwojtowicz, 2000). Studies have shown the drug 
binding sites of P-gp to be localized to the cytoplasmic membrane leaflet (Shapiro and 
Ling, 1994; Lugo and Sharom, 2005a).  
The 12 TM domains comprise the drug binding site of P-gp. Cysteine-scanning 
mutagenesis (Loo and Clarke, 1999; Loo and Clarke, 2001; Loo et al., 2003; Loo et al., 
2005; Loo and Clarke, 2005; Loo and Clarke, 2005a) and fluorescence resonance energy 
transfer (FRET) studies (Lee et al., 2002) have given insights into various interactions 
that take place at this site. 
Cysteine-scanning mutagenesis has shown that TMs 4, 5 and 6 in the N-terminal half and 
TMs 9, 10, 11 and12 in the C-terminal line the drug binding pocket. (Loo and Clarke, 
2005). The vanadate trapped complex of P-gp, which is thought to structurally resemble 
the catalytic transition state suggests that the TM helices rotate during the catalytic cycle 
(Loo and Clarke, 2001; Rosenberg et al., 2001; Loo and Clarke, 2005a). The rotation of 
helices 2/11 and 5/8 open and close the drug binding pocket (Loo and Clarke, 2005a). 
Mutations on face of these TM domains alters substrate binding indicating that specific 
residues may be involved in this process (Loo and Clarke, 1993; Ambudkar et al., 1997).  
The drug binding sites of P-gp are predicted to lie in a large funnel-shaped binding 
pocket (Ambudkar et al., 1997; Loo and Clarke, 2001; Loo and Clarke, 2005). A similar 
shape has also been suggested for the bacterial protein sav1866 (Dawson and Locher, 
2006) and more recently, mouse P-gp (Aller et al., 2009). X-ray crystallography of mouse 
P-gp suggests an internal cavity of 6000 Å3 with a separation of 30 Å between the two 
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NBDs (Aller et al., 2009). For drugs which are usually less than a nanometer in size 
(vallet-Regí et al., 2007), this would mean that they would easily be able to access the 
binding site, their association rate being limited by lipid lateral diffusion. The association 
rate (k1) for P-gp has been found to be very high (Tran et al., 2005; Acharya et al., 2006), 
which supports this theory. 
Cysteine scanning mutagenesis and chemical cross-linking studies show that the human 
P-gp occurs in a domain architecture with the long intracellular loop of TM2 making 
contact with NBD1, a structure seen in sav1866 as well (Zolnerciks et al., 2007). There 
appears to be an interface formed between this loop in TM2 and NBD1, which is 
sensitive to the added nucleotide. It is, thus, suggested that the interface may be relevant 
to the function of the transporter, although its exact function is still unknown. 
The presence of two distinct binding sites within the binding pocket of P-gp has been 
proposed (Shapiro and Ling, 1994; Lugo and Sharom, 2005a; Lugo and Sharom, 2005b). 
These have been designated the R-site, due to its preference of rhodamine 123, and the 
H-site, due to its preference for Hoechst 33342. Both these sites have been localized close 
to the membrane-cytosol interface. A FRET approach estimating distance separating 
bound Hoechst 33342 form a fluorescent probe linked covalently to the catalytic site, 
suggests that the drug binding site is within the cytoplasmic leaflet (Qu and Sharom, 
2002). 
 
3.4 P-gp substrates and modulators 
P-gp has the ability of interact with several substrates and modulators that appear to be 
structurally unrelated. These are generally nonpolar, weakly amphipathic compounds, 
 13
and include natural products (such as flavonoids), anticancer drugs (such as paclitaxel, 
vinblastine), steroids (such as progesterone, cortisol), fluorescent dyes (such as 
rhodamine 123, Hoechst 33342), linear and cyclic peptides (such as leupeptin, pepstatin 
A), and ionophores (such as gramicidin D, nonactin) (Sharom, 2007) 
There has been one study to that suggests that a set of well defined structural elements is 
required for an interaction with P-gp (Seelig, 1998). The author looked at the spatial 
relationship between electron donor groups in 100 P-gp substrates. She defined a type I 
unit as one that consists of two electron donor groups with a spatial orientation of 2.5 ± 
0.3 Å and a type II as one that consists of either two electron donor groups with a spatial 
orientation of 4.6 ± 0.6 Å or three electron groups with a spatial separation of the two 
outer groups at 4.6 ± 0.6 Å. She concludes that all substrates have at least one type I or 
one type II unit and can have up to 8 such units. She also concluded that those molecules 
which have at least one type II unit are predicted to be inducers of P-gp overexpression. 
This gives us a basis to screen additional drugs that may be P-gp 
substrates/inhibitors/inducers and possibly design new substrates with desired properties. 
 
3.5 Drug efflux by P-gp 
Two distinct models have been proposed to describe the catalytic cycle of P-gp: the 
hydrophobic vacuum cleaner model and the lipid flippase model. These models were put 
forth to oppose the idea that the initial interaction between the substrate and P-gp occurs 
at the aqueous cytoplasmic phase and it is then transported to the aqueous cytosolic phase 
through a distinct hydrophilic pore formed by the TM domains (Higgins and Gottesman, 
1992). It must be noted that both models require that drug molecules partition into the 
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membrane, from where it is extruded. The fact that the catalytic site appears to be in the 
cytoplasmic leaflet supports these model. Also, several transport experiments provide 
evidence that this is indeed the case (Bolhuis et al., 1996; Shapiro and Ling, 1997; 
Shapiro and Ling, 1998; Omote and Al-Shawi, 2006). However, we will see that the 
mechanism of extrusion as proposed by the two models is different 
 
3.5.1 The hydrophobic vacuum cleaner model 
The hydrophobic vacuum cleaner model was put forth based on the observation that iodo 
naphthalene azide (INA), a non-specific hydrophobic affinity probe can get 
photoactivated by energy transfer from P-glycoprotein substrate daunorubicin (Raviv et 
al., 1990). Since INA is hydrophobic and found within the membrane, it was suggested 
that the interaction between daunorubicin and INA occurs within the membrane. Hence it 
was proposed that P-gp is a hydrophobic “vacuum cleaner” that “sucks” drugs out of the 
membrane and extrudes it to the aqueous cytosol. 
One may note that P-gp substrates are amphipathic in nature. They are thought to 
spontaneously “flip-flop” from the outer cytosolic to the inner cytoplasmic leaflet. Being 
amphipathic, they do not distribute uniformly in the lipid core but are concentrated in the 
interfacial region of the membrane (Belinsky et al., 2005). Drugs then gain access to the 
binding sites, which are believed to be located in the interfacial region, and then get 
effluxed into the aqueous cytosol. Thus P-gp works to “separate” the drug from the lipid 
to the aqueous phase. Molecular dynamic simulations performed by Omote and Al Shawi 
suggest that verapamil stabilizes at the interfacial region and may hence be recognized 
and effluxed by P-gp from this region (Omote and Al-Shawi, 2006). 
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3.5.2 The lipid flippase model 
It was also proposed that P-gp may operate as a drug flippase (Higgins and Gottesman, 
1992). In this model P-gp is thought to move hydrophobic drug molecules from the 
cytoplasmic leaflet to the cytosolic leaflet. If P-gp maintains higher drug concentration in 
the cytosolic leaflet than in the cytoplasmic leaflet, then equilibration of drug between the 
membrane and the aqueous phase would result in the drug concentration gradient 
observed (Sharom, 2007). 
MDR3, a lipid flippase known to transfer phosphatidyl choline to the plasma membrane 
(van Helvoort et al., 1996) has 80% homology to P-gp. Thus it seems reasonable that P-
gp may also be a lipid flippase. Several studies have also suggested that P-gp is capable 
of moving fluorescent NBD-labeled phospholipid derivatives and glycosphingolipids 
(van Helvoort et al., 1996; Bosch et al., 1997; van Meer et al., 1999). Reconstituted P-gp 
in lipid bilayer vesicles  has been shown to act as an outwardly directed flippase for 
NBD-labeled phospholipid derivatives and glycosphingolipids (Romsicki and Sharom, 
2001; Eckford and Sharom, 2005). 
 
3.5.3 ATP hydrolysis and transport 
Whether as lipid flippase or a hydrophobic vacuum cleaner, P-gp requires the hydrolysis 
of ATP to efflux drug. Transport can be broken down to: entry of substrate into the 
binding pocket which lies within the cytoplasmic leaflet, conformational changes in P-gp 
driven by ATP binding/hydrolysis, and release of drug to either the outer leaflet or the 
aqueous phase. Conformational changes on P-gp are required for drug efflux. It involves 
the reorientation of P-gp from the cytosolic membrane to the cytoplasmic membrane 
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(Loo and Clarke, 2005a; Sharom, 2007). The ATP hydrolysis cycle is superimposed on 
the transport cycle. This involves ATP binding, formation of the ATP sandwich dimer, 
hydrolysis, dissociation of Pi, and dissociation of ADP. 
It is first proposed that the hydrolysis of ATP is required only for the “power stroke” 
which results in the conformational change (Ramachandra et al., 1998). Others suggest 
that the ATP hydrolysis is important to “reset” the P-gp rather than bring about the 
conformational change (Higgins and Linton, 2004; Loo and Clarke, 2005; Loo and 
Clarke, 2005a). A general sequence of ATP hydrolysis is proposed (Sauna and Ambudkar, 
2007): 
Binding of ATP at the two NBDs results in the formation of the sandwich dimer, which is 
the first step (Sauna and Ambudkar, 2007). FRET studies indicate that the C-motif of 1 
NBD domain is close the Walker A sequence of the other NBD, which supports the 
above claim (Qu and Sharom, 2002). Asymmetrical occlusion of the ATP causes a switch 
of the conformation from one of high to low substrate affinity. Hydrolysis of the 
occluded ATP resets P-gp to its original confirmation. 
Senior et al. (1995) proposed an alternating-site mechanism for P-gp. ATP hydrolysis 
drives transport by relaxing a high energy intermediate. For each drug molecule 
transported, 1 ATP molecule is hydrolyzed. They later proposed cooperativity between 
the binding sites (Senior et al., 1998). 
It is unclear which event leads to the “resetting” of P-gp. One train of thought that that 
release of Pi or ADP results in the “resetting” of P-gp (Higgins and Linton, 2004). 
Another train of thought proposes that ATP hydrolysis can be used both for transport as 
well as to reset the protein to its original conformation (Hrycyna, 2001; Rosenberg et al., 
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2005; Sauna and Ambudkar, 2007). Further studies need to be done to confirm either 
model.  
It is imperative that conformational communication exists between the TM domains and 
NBDs so that binding of the drug induces ATP hydrolysis for efflux. Studies have shown 
that drug binding in the TM domains induce long range conformational changes in the 
NBDs (Loo et al., 2003; Zolnerciks et al., 2007), which serve as a direct evidence of this 
phenomenon. 
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4. Subcellular Systems used to Study the Kinetics of Drug Efflux via P-gp 
 
4.1 Use of purified proteins reconstituted in lipids and membrane vesicles 
Proteins reconstituted in lipids and membrane vesicle preparations serve as good systems 
to study the biochemical and biophysical aspects of membrane-bound enzymes and 
transporters (Banerjee and Datta, 1983). In such a system, since all other components of a 
cell are lacking, we can carefully dissect the biophysical and biochemical aspects of the 
protein of interest, without the interference of other genes/pathways that may influence 
its expression.  
There have been several studies using P-gp (or its homologues) in proteoliposomes and 
inside-out membrane vesicles. Listed are a few examples: Ambudkar (1995) looked at the 
efflux of radiolabelled vinblastine in P-gp reconstituted in liposomes. Schlemmer and 
Sirotnak (1994) performed similar studies with the mouse homolog, MDR3.  Omote and 
Al Shawi (2006) measured turnover numbers (i.e., the maximum number of drug 
molecules effluxed per P-gp molecule per unit time) for verapamil, Hoechst 33342, 
colchicine, rhodamine 123 and daunorubicin for P-gp reconstituted in liposomes. 
Aanisma and Seelig (2007) measured P-glycoprotein activity in inside-out vesicles 
formed from plasma membranes of MDR1-transfected mouse embryo fibroblasts (NIH-
MDR1-G185). 
Plasma membrane vesicles have proved useful in determining if a certain molecule is a 
substrate for P-gp. Attempts to couple drug uptake with ATPase activity has been done. 
Real time measurements on the transport of tetramethylrosamine (TMR) coupled with 
ATP hydrolysis has been performed (Lu et al., 2001). The authors looked at transport of 
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1µM TMR with increasing ATP concentration, up to 1mM. The data was then fitted to 
Michaelis-Menten curve to derive a Km for ATP transport. Similar studies were 
performed to correlate the uptake of Hoechst 33342 to ATPase activity (Wang et al., 
2000). 
One must exercise caution when performing such studies and/or interpreting data. Firstly 
one must keep in mind that fluorophores in high concentration tend to get quenched. 
Thus the measure of the amount of a fluorophore transported into a vesicle may not be 
the best measure for transport. One must also keep in mind that substrates of P-gp being 
hydrophobic in nature may interact with the membrane itself. Also membrane vesicle 
system, due to their simplistic nature, do not emulate in vivo conditions. The kinetic 
parameter values, i.e., Vmax and Km are calculated for ATP hydrolysis. It is presumed 
there is a 1:1 correlation between ATP hydrolysis and drug transport, i.e., for every ATP 
hydrolyzed, one drug molecule is transported. However, as I have stated in section 2.5.3, 
it is still unclear if 1 or 2 ATP molecules are required for a complete catalytic cycle. 
Another drawback is that it is difficult to perform saturation and inhibition studies in this 
system. For such studies, data acquisition must be done at times representing “initial rate 
of transport” to minimize effects of substrate leaking back out of the cell (Gutierrez et al., 
1996). In vesicles this can happen within one minute. Hence one needs to be cautious of 
the measurements made. 
 
4.2 Use of confluent cell monolayers to study transport 
Cells grown to single layer confluence on porous membranes serve as good systems to 
study drug efflux by membrane transporters such as P-gp.  This system is often chosen 
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because it is physiologically relevant and requires no biochemical manipulations to 
measure transport (Tran et al., 2005). Such cells grow in a polarized manner with the 
basolateral side on the porous membrane (Butor and Davoust, 1992). P-gp is known to be 
expressed in the brush border of the apical side. This it is possible to study transport 
vectorially, i.e. from the apical to basolateral (A>B) or basolateral to apical (B>A) side. 
Confluent monolayers of several different cell lines have been employed to study the 
kinetics of drug efflux via P-gp. Confluent monolayer of the human colonic 
adenocarcinoma (Caco-2) cell line (Hunter et al., 1993; Stephens et al., 2001; Collett et 
al., 2004), the murine NIH/3T3 fibroblasts transfected with the human MDR1 gene (Stein 
et al., 1994; Ambudkar et al., 1997), and the Madin Darby Canine Kidney cell line 
transfected with the human MDR1 gene (MDCK II-hMDR1) (Ito et al., 1999; Tang et al., 
2002a; Tang et al., 2002b; Tran et al., 2004; Tran et al., 2005; Acharya et al., 2006; 
Acharya et al., 2008) have been used to understand the kinetics of drug efflux by P-gp.  
Studies in the NIH3T3 fibroblasts determine the vinblastine stimulated ATPase activity 
of P-gp (Ambudkar et al., 1997). The authors determined that 2.8 molecules of ATP are 
hydrolyzed for each vinblastine molecule effluxed. Similar findings have been reported 
from studies performed in the Caco-2 cell line (Hunter et al., 1993; Adachi et al., 2001). 
Extensive studies done on the MDCK cell lines expressing Organic Anion Transporting 
Polypeptides (OATPs, another membrane transporter) (Goh et al., 2002; Bartholome et 
al., 2007) as well as the MDCK II-hMDR1 cell lines (Tran et al., 2004; Tran et al., 2005; 
Acharya and Bentz, 2007; Acharya et al., 2008) have allowed the development of data 
based mathematical models of transport.  
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MDCK II-hMDR1 cells were developed since studies of drug efflux by P-gp across a 
confluent monolayer of Caco-2 cells were complicated by the presence other transporters 
such as cytochrome P450 3A4 (Tang et al., 2002a). Initially, there was some concern as 
to whether MDCK II-hMDR1 cells suitably emulated human mucosa. Comparison of P-
gp expression and transport in Caco-2 and MDCK II-hMDR1 cells confirmed that both 
cell lines are similar with respect to these aspects (Tang et al., 2002a; Tang et al., 2002b). 
It is clear that confluent cell monolayers are a better system than membrane vesicles to 
study drug efflux. However, for appropriate kinetic studies in these systems, it is 
imperative that the integrity (or confluency) of the monolayer is maintained. This is often 
done by monitoring the transport of substances such as lucifer yellow (Tran et al., 2004; 
Tran et al., 2005; Acharya et al., 2006; Acharya et al., 2008), radiolabelled mannitol 
(Tang et al., 2002a; Tang et al., 2002b) or radiolabelled inulin (Bartholome et al., 2007). 
If the monolayer is intact, then the transport of these substances from one chamber to 
another would be very low. 
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5. Assays to Study P-gp Transport Activity 
 
In this section I shall talk about four different techniques, or models if you may, that have 
been extensively used to explain the kinetics of drug efflux by P-gp. I shall start with the 
simplest and build up to the most complex of these assays/models. 
 
5.1 The use of linear compartmental models to elucidate P-gp activity 
A compartmental system is a system comprising a finite number of compartments, each 
of which is homogeneous or “well mixed”. The compartments interact by exchanging 
material, with possible inputs from the “environment”. Mass balance conditions holds for 
all transfers (Jacquez, 1988). 
Linear compartmental models are the simplest models designed to explain the exchange 
of material, in our case the transport of xenobiotics, from one compartment to another. A 
two-compartmental system would successfully describe drug transport in vesicles, with 
the vesicle being one compartment and the solution in which it exists being the other. 
Confluent cell monolayers can be described by the three-compartmental model. Here the 
basolateral chamber would be one chamber, the cell cytoplasm the second and the apical 
chamber the third. One important aspect of the linear compartmental model is that the 
rate of transport is described by a first order equation (Anderson, 1983; Jacquez, 1988). 
The linear compartmental model allows us to predict if the molecule whose transport is 
being measured is a P-gp substrate. The supposition here is that the molecule is not a 
substrate for any other protein that may be expressed in the cell. Confluent monolayer 
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systems are used for this purpose. One of the chambers, either basolateral or apical, is 
designated as the donor and the other as the receiver. 
The “permeability” of substance in both directions, i.e. from the apical to basolateral side 
(A>B) and basolateral to apical side (B>A) is determined. The ratio of permeabilities, i.e. 
(B>A)/ (A>B), is defined as the efflux ratio. If the molecule is transported purely by 
diffusion and P-gp is not involved then the efflux ratio would be equal to 1. However, if 
P-gp is involved, then the efflux ratio would be greater than 1, since P-gp preferentially 
effluxes to the apical chamber.  
Linear compartmental models have been used to show the involvement of P-gp in drug 
transport (Kuh et al., 2000; Adachi et al., 2001; Tang et al., 2002a; Johnson et al., 2003; 
Collett et al., 2004; Bachmeier et al., 2006; Bartholome et al., 2007; Sun and Pang, 2008). 
The advantage of the linear compartmental model is that it is simple and hence easy to 
use. Perhaps therein lies its disadvantage as well. Due to its simplicity, this model does 
not tell us anything about the kinetics of the efflux itself. 
 
5.2 The steady-state Michaelis-Menten model 
To gain some information on the kinetics of P-gp, we need to diversify into a non linear 
model. One that comes into mind, since it has been well established in its use in 
biological systems, is the Michaelis-Menten model. P-gp is generally assumed to follow 
the standard Michaelis-Menten reaction (Stein, 1997; Ho et al., 2000; Ambudkar et al., 
2003; Bentz et al., 2005; Tran et al., 2005; Acharya et al., 2006).  The advantage of this 
model over the linear compartmental model is that we obtain two parameters, Vmax, the 
maximal rate of drug efflux, and Km, the concentration of drug required for P-gp to 
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function at half its maximal velocity, that give us some idea about the kinetics of drug 
efflux. Vmax/Km is described as the intrinsic clearance rate (Bachmeier et al., 2006), i.e. 
the number of drug molecules effluxed per unit time.  
In order to generate the Michaelis-Menten curve, the experimental set-up requires that we 
calculate the rate of efflux (V) at several different drug concentrations (S). We, of course, 
assume that the calculation of V is done when the transport is at the initial stages. The 
plot of V vs. S allows us to determine Vmax and hence Km. Thus by making an 
experimental measurement at just one time point, albeit for multiple concentrations, we 
are able to get an insight on the kinetics of drug efflux.  
Like the linear model, the Michaelis-Menten model has been extensively employed to 
gain an insight into the catalytic cycle of P-gp (Demant et al., 1990; Horio et al., 1990; 
Hunter et al., 1993; Ambudkar, 1995; Ambudkar et al., 1997; Doppenschmitt et al., 1999; 
Adachi et al., 2001; Jang et al., 2001; Johnson et al., 2003; Collett et al., 2004; Sun and 
Pang, 2008).Some efflux studies are combined with studies of ATP hydrolysis in order to 
correlate the two  (Ambudkar et al., 1997; Adachi et al., 2001). However this analysis 
does not give us any means to correlate the kinetics to the catalytic cycle of P-gp. 
One must keep in mind that the Michaelis-Menten kinetics was developed to elucidate 
the catalysis of substrates by soluble enzymes which bind substrate directly from the 
surrounding aqueous environments. It has been successfully applied to explain the 
transport kinetics of transporters such as glucose permease (Stein, 1997), which bind to 
their substrate directly from the aqueous phase. In 2005, Bentz et al. showed that the 
experimentally measured Km value cannot be correlated to the molecular Km value as 
determined by the elementary rate parameters  (Bentz et al., 2005). The determination of 
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an accurate Km value is important to understand the efficacy of the drug in vivo. Thus the 
application of the Michaelis-Menten model to describe P-gp kinetics is questionable. 
At this point, I would like to state that a recent study by Sun and Pang (2008) refutes the 
claim made by Bentz et al. (2005). However, in the course of my study, I will show that 
the original results of Bentz et al. (2005) do hold true, provided some inherent conditions, 
as dictated by the Michaelis-Menten model, are met. 
 
5.3 The IC50 assay 
In drug transport studies, the half maximal inhibitory concentration (IC50) refers to the 
concentration of one drug (inhibitor) required to reduce the efflux of another (substrate) 
by 50%. IC50 assays are typical assays to demonstrate drug-drug interactions (Acharya 
and Bentz, 2007).  This makes IC50 assays clinically relevant. The IC50 is determined by 
constructing a dose response curve for the substrate and then examining the effect of 
different inhibitor concentrations on reversing the activity of the substrate.  
The cell based bidirectional assay is one universally accepted by the industry, and 
approved by the Food and Drug Administration, U.S.A. to perform IC50 studies 
(Balimane et al., 2008). However, several different calculation methods exist (Kim et al., 
1999; Polli et al., 2001; Perloff et al., 2003; Troutman and Thakker, 2003a; Troutman and 
Thakker, 2003b; Rautio et al., 2006; Balimane et al., 2008; Hsiao et al., 2008), leaving 
considerable room for error. 
Thus IC50 assays serve as a vital tool to understand drug-drug interactions. Yet, like the 
Michaelis-Menten model, it fails to provide any correlation between the efflux kinetics 
and the transport mechanism. 
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5.4 The minimal comprehensive mass action kinetic model for P-gp 
Recently, a new model to elucidate the kinetics of drug efflux via P-gp was developed. 
This was the minimal comprehensive mass action fitting model (Tran et al., 2005; 
Acharya et al., 2006; Acharya et al., 2008). This model employed the Michaelis-Menten 
kinetics. However by not imposing the steady state conditions, the authors were able to 
simultaneously determine all parameters that describe the efflux process, via a 
comprehensive fitting technique. Determining all these parameters allows a better 
understanding of the structure-function relationship of the protein. For example, the 
authors found that the binding constant for P-gp is low (Tran et al., 2005; Acharya et al., 
2006). Such an outcome would be expected for a protein that is capable of effluxing 
several, structurally unrelated compounds. 
The limitation of the minimal mass action model is that for successful determination of 
the parameters, experimental data over 9 points ranging up to 4-6 hours had to be 
generated. Fitting of the each data set took 7 – 9 days, thus requiring several months to 
obtain the parameter set. Even then, fitting of all datasets resulted in a small range of 
values for each parameter. It did not give a lone vector of parameter values. 
We address some of these issues in this study. 
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6. Specific Aims 
 
Models serve a purpose of providing a quantitative aspect to a qualitative analysis.  
Mathematical models that are employed in biology help us to understand certain aspects 
of a complex biological processes by “cutting out” some of the noise by making certain 
assumptions. Models may also allow us predict the behavior of a complex system under 
real life conditions. 
For successful mathematical/computational modeling of a biological system one must 
take into account all possible biological constraints. Every assumption made in this 
model should be biologically relevant. Such a model would be able to explain 
observations made in vivo. In addition, to effectively extrapolate a model based on in 
vitro experimental conditions to in vivo conditions, one must understand the limitations 
of the model. 
With this in mind there are three main aims of this study: 
(1) To understand the basis for the “range” that we get from the minimal mass action 
fits, rather than a single vector of values. It is particularly important to understand 
the effect of experimental error on the “range” of fits obtained for optimal 
extrapolation in vivo 
(2) To compare and contrast the minimal mass action model and the steady-state 
Michaelis-Menten model. Since both models employ the Michaelis-Menten 
equations, when steady-state conditions are imposed on the minimal mass action 
model, it should give the same results as seen when employing the Michaelis-
Menten model. However the results obtained by Sun and Pang (2008) via their 
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simulations contradict results obtained by Bentz et al. (2005). I shall attempt to 
address these differences in this study. 
(3) To understand the effect of changing microvilli morphology on drug efflux 
through a confluent monolayer of cells, via simulations. Both Tran et al. (2005) 
and Acharya et al. (2006) employed the minimal mass action model to obtain the 
kinetic parameters of 3 drugs, amprenavir, quinidine, and loperamide. However, 
Acharya et al. (2006) found that the passive permeation rates and the 
concentration of P-gp directly involved in drug efflux (efflux active P-gp; term 
discussed later), that they obtained via fitting were twice those of Tran et al. 
(2005). Simultaneous changes in both these values was attributed to changes in 
microvilli morphology (Acharya et al., 2006). We aim to determine how much the 
microvilli morphology must change in order to detect such changes, via 
simulations. 
 
A successful establishment and understanding of these models will allow us to 
successfully extrapolate the findings of these models obtained under in vitro settings to in 
vivo conditions. 
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7. Summary of Research Papers 
 
The minimal mass action model was developed to understand the kinetics of drug efflux 
by P-gp constitutively overexpressed in the Madin Darby Canine Kidney II cell lines. The 
experimental procedure involved studying drug efflux through these cells (designated 
MDCK II-hMDR1) to confluency on a 12 well Costar-Transwell plates with 
polycarbonate membrane inserts (0.4um pore size, cell growth area 1.13 cm2) (Tran et al., 
2005; Acharya et al., 2006).  The advantage of using such a system was that the cells 
grew in a polarized manner with their basement membrane attached to the insert. This is 
turn allowed the authors to test drug efflux in either, apical to basolateral (A>B) or 
basolateral to apical (B>A) direction. Cells were incubated with radiolabelled drug in 
either one chamber (called the donor) and transport to the other chamber (the receiver) 
was determined. Experimental data was collected over 4 – 6 hours at regular time points. 
This involved collecting sample aliquots to determine drug concentration, at nine time 
points. 
The data was then fit through a two-step hierarchal fitting model. The basis for this model 
was the Michaelis-Menten reaction which is described as: 
 
where T0 is the empty transporter, CPC is the concentration of the drug in the apical inner 
monolayer, T1 is the transporter bound by the substrate and CA is the substrate after efflux 
into the apical monolayer. Note that the total P-gp concentration, T(0) is the sum of T0 
and T1. The supposition of steady state was eliminated. Thus it employed the non-steady 
state kinetic equations (that are used to derive the steady-state Michaelis-Menten 
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equations, assuming steady state). The virtue of using these equations was that the 
authors were able to determine any and every parameter that describes the efflux process 
thus giving insights into the structure-function relationship of P-gp. All parameters were 
fitted for, simultaneously. 
The first step of the fitting routine involved fitting the parameters influencing the 
“forward”, B>A transport (T(0), k1, and k2) only since the fitting range for the “forward” 
reaction were not likely to be sensitive to the reverse parameters, an observation that they 
extended from membrane fusion studies. (Bentz and Nir, 1981; Bentz et al., 1983). This 
reduces the number of parameters to be fit in the first step. The fitting gave them a range 
of values within which each parameter could lie. They then fit the “reverse” A>B data to 
determine kr, with the added constraint that the forward parameters can only vary within 
the range obtained by the forward fits. This gave them a range for kr. They repeated this 
process three times, decreasing the tolerance at each step. The range for each parameter 
value was fixed at that obtained from the previous step. Each experimental dataset was 
fitted individually. 
The virtue of this model is that it gave a complete understanding of the kinetic process, 
by allowing all parameters to be determined. However two main limitations existed: 
(1) It took 7~9 days to fit each dataset on a 2.8 GHz PC (Tran et al., 2005). Thus it 
would take several months to obtain a complete parameter set for a drug. 
(2) The fitting routine always provided a range of values for each parameter rather 
than a lone vector of best fits. 
It is important to understand the basis of this range 
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7.1 Summary of Paper 1 
The ultimate goal of the lab is to be able to advocate the use of the minimal mass action 
model to understand the kinetics of drug efflux of any membrane transporter. However, 
before that is possible, a thorough understanding of the limitations of the model is 
necessary. Also, it does not help if it takes several months to get the results of an 
experiment, especially in todays fast paced world. In the first chapter of this study we aim 
to understand and overcome these limitations. 
In order to shorten the amount of time taken to fit the datasets, a particle swarm fitting 
technique was designed. As pointed out, there are several parameters that need to be 
simultaneously determined. We know that the fitting surface for a large multivariate 
parameter space may have several peaks and valleys (Tran et al., 2005). The way the 
particle swarm works is by sending an “army” of particles into this “terrain” to look for 
the “deepest valley” within the “foothills”. The advantage of this fitting routine is that we 
were able to fit all datasets, for all drugs, simultaneously, rather than each dataset 
individually as with the hierarchal fitting technique (Tran et al., 2005; Acharya et al., 
2006). I must point out that even the swarm-process technique has two steps to the fit. In 
the first step of the fit we are interested in obtaining a consensus fit for T(0) and k1 only, 
although all parameters are simultaneously fitted at this step. These two parameters have 
been shown to be the same for all drugs studied (Tran et al., 2005; Acharya et al., 2006). 
It is also important to point out that to determine these two values, we simultaneously fit 
all the datasets, for all drugs. However, since the other parameter values are drug 
dependent, in the next step we fit for these values with the all datasets for each individual 
drug only. In addition, at this step we fix the T(0) and k1 values to a consensus value 
 32
obtained from the first step. We are able to reduce the total time for the determination of 
all parameters to a matter of 4 – 7 days on a 2.8 GHz PC, rather than several months. 
We find that even by employing this fitting technique we get a range of possible fits for 
each parameter. The coefficient of variation of each individual fit is the same as any other 
fit, i.e. not individual fit is better than any other. Hence we embark on understanding why 
we get a range of values for each parameter rather than a lone vector of best fits. 
One may attribute the range to inherent experimental error in the datasets. The easiest 
way to determine if this is indeed the case is by employing the same fitting technique to 
perfect data (one lacking error). 
Based on the consensus value for each parameter obtained by fitting the experimental 
dataset, we generated perfect data and subjected it to the same fitting routine. We find 
that even fitting perfect data results in a closed range of parameter values rather than a 
lone vector of perfect fits. The range is similar to that seen by fitting experimental data. 
This shows that the “range” is not due to error that may be present. 
We next examined the fitting surface obtained by changing the T(0) and k1 value only; all 
other parameter values were fixed. This was done for both experimental as well as 
simulation data sets. We find that when only two parameters are allowed to be varied, the 
fitting surface predicts a deep valley, i.e. we were able to get a very tight range within 
which T(0) and k1 values could vary. This range was not significantly affected by 
experimental error. We also found that the range of values obtained by fitting the 
experimental datasets of digoxin alone was greater than that obtained by fitting only the 
quinidine datasets. As Acharya et al. (2006) pointed out, additional transporters for 
digoxin exist in the basolateral as well as apical surfaces of the MDCK II-hMDR1 cell 
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line. Thus, to effectively elucidate the efflux of digoxin via this cell line, additional 
parameters need to be fitted. Our results indicate that if the number of parameters to be 
fitted increases, the range of each individual parameter increases as well. 
Our conclusion, therefore, is that experimental error is not responsible for generating a 
“range” in the fits. Rather it is the process of globally optimizing the fits, i.e. attempting 
to simultaneously determine several parameters that results in a range of fits rather than a 
lone vector best fits. 
 
7.2 Summary of Paper 2 
The steady-state Michaelis-Menten model, it is widely assumed, can be effectively 
employed to explain drug efflux by membrane transporters such as P-gp. It is important 
to keep in mind that this model was designed to explain the catalysis of substrates by 
soluble enzymes which bind substrate directly from the surrounding aqueous 
environments. However, its application to kinetics of drug efflux by transporters that pick 
drugs from the membrane rather than the aqueous cytosolic environment is unclear. 
Although this kinetic model has been effective in explaining the kinetics of transport by 
glucose permease (Stein, 1997) and the ATPase activity of P-gp (Senior et al., 1995; Al-
Shawi et al., 2003; Loo et al., 2003), one must keep in mind that these processes occur 
from or at the cytosol itself. 
Bentz et al. (2005) used the minimal mass action model to generate model 
“experimental” data. They then fitted this data to an Eadie-Hofstee curve. This allowed 
them to compare the “experimental” Vmax and Km values to the molecular Vmax and Km 
values, as determined by the elementary rate constants. They found that while the 
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“experimental” and molecular Vmax values could be correlated, the same was not true for 
the Km values. Sun and Pang (2008) employed simulations of the Michaelis-Menten 
model to generate data and subject them to the same Eadie-Hofstee fit. They found that 
while the “experimental” and molecular Km values could be correlated, the same was not 
true for the Vmax values, a result opposite to that seen by Bentz et al. (2005). 
In order to advocate the use of the minimal mass action model, we need to address these 
contradictory results, especially since the results were obtained by a universally accepted 
model. This was the objective that we aimed to accomplish in the second chapter of this 
study. 
Before I proceed I must point out that the conditions simulated by Sun and Pang (2008) 
were different from those simulated by Bentz et al. (2005). Some of these conditions may 
not be biologically appropriate. However, rather than question their relevance, we wanted 
to test whether a difference in results does exist just based on the model employed. Thus 
we tested over all possible range of values used in both studies. 
Using both models, we generated “experimental” data via simulations. This was then fit 
to an Eadie-Hofstee curve. We found that the Eadie-Hofstee plot is a curve, rather than a 
linear decreasing line as seen for soluble enzymes. This basically means that only the 
velocities obtained for the highest substrate concentrations can be used for the 
determination of the correct “experimental” Vmax. It is also important to note that in order 
to determine the appropriate Vmax, at least 70% of the protein be saturated, an inherent 
requirement of the Michaelis-Menten kinetics. If appropriate substrate concentrations are 
not used, then Vmax would be overestimated. The determination of the correct Vmax is 
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required to determine the right Km. For this, the curvature of the Eadie-Hofstee plot must 
be accounted for (Bentz et al., 2005).  
We find that irrespective of the model employed to generate the data, there is a 
correlation between the “experimental” and molecular Vmax but not between the 
“experimental” and molecular Km, i.e. the correlations seen by Bentz et al. (2005) hold 
true. This is of course, subjected to the fact that the substrate concentrations used to 
generate the data were high enough to account for 70% of protein saturation. 
We also find that a relationship to correlate the molecular and experimental values, and 
the substrate concentration, does exist, albeit complex. 
 
7.3 Summary of Paper 3 
Now that I have addressed two of the main concerns that pose a challenge to the 
acceptance of the minimal mass action model, I wanted to address two important 
experimental observations that were made during the course of application of this model. 
The minimal mass action model directly determines the expression level of P-gp in the 
membrane via fitting. Tran et al. (2005) reported P-gp levels that were 90% lower than 
those seen by western blotting in NIH/3T3 cells (Ambudkar et al., 1997). They claim that 
the P-gp expressions that they determined correspond to those involved in effluxing drug 
directly into the apical chamber where it instantly equilibrates. This would, thus, 
represent P-gp only at the tips of the microvilli (which contribute to ~10% of the total cell 
surface). They hypothesize that drug efflux elsewhere down the microvilli would get 
absorbed. 
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When Acharya et al. (2006) repeated the experiments conducted by Tran et al. (2005), 
they found that the passive permeability and P-gp expression values that they determined 
were twice those determined by Tran et al. (2005). Both values changed by the same 
extent. To account for this, they hypothesized that the surface area of the brush border 
had changed affecting both passive permeability as well as P-gp expression. 
In the third chapter of my study I aim to look at the effect of changing microvilli 
morphology on drug efflux via simulations. 
Microvilli are dynamic structures known to undergo spontaneous degeneration and 
assembly (Mooseker, 1985). Several factors affect the expression of microvilli (Lange et 
al., 1990; White et al., 2000; Witowski et al., 2001; Tyska and Mooseker, 2002). 
However, it is important to point out that majority of these studies report changes in 
length of microvilli in the presence of these substances rather than expression densities. 
There have been no studies that quantitate the effects of the presence of a substance and 
changes in microvilli structure. Thus rather than divulging directly into the uncertain 
experimental world, we wanted to arm readers with an idea of what they might expect if 
such a study is undertaken. 
We determine the probability of a molecule escaping as the ratio of the number that 
escape to the total number effluxed, where “escape” is defined as the molecule being a 
certain distance away from its closest absorbing surface. Consequently “absorption” is 
defined as the molecules being within a certain distance of the closest absorbing surface. 
These values have been explained in the text of the paper. We determine the effect of 
changing microvilli height and the separation distance on the probability of escape. 
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We first looked at the probability that a molecule “effluxed” at a specific region of the 
microvilli would escape into the apical chamber. By comparing this probability for 
different regions we can determine an “escape profile” as we travel down the microvilli. 
We find that most of the molecules effluxed from the tips of the microvilli escape while 
those released closer to the base of the microvilli do not. At a fixed separation distance, 
as the height increases, number of a molecule escaping from the base of the microvilli, 
decreases. However, if we increase the distance of separation between microvilli of fixed 
heights, then we start seeing more escapes from the base. This is physiologically 
expected and hence a measure of the strength of our simulation.  
We also find that when the height decreases, and the separation distance increases, the 
number of molecules escaping per unit area of the membrane increases. How ever this 
increase is not indefinite. We find that there exists a crucial height to separation distance 
ratio that affects the number of escapes per unit area. 
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Paper 1: Abstract 
 
P-glycoprotein, a human multidrug resistance transporter, has been extensively studied 
due to its importance to human health and disease. Recently, a minimal mass action 
kinetic model was employed to elucidate the kinetics of drug uptake and efflux by this 
protein. The advantage of this technique over those used previously (such as steady state 
Michaelis-Menten analysis) lies in the fact that the minimal mass action kinetic model is 
the only technique that is able to determine the elementary kinetic parameters thereby 
giving a better understanding of the transport mechanism. This technique simultaneously 
fits all necessary parameters that describe drug efflux via P-gp. Each parameter has a 
wide range of potential values. The best fit is computed as that vector of parameter values 
which gives the least coefficient of variation between experimental data and simulation 
model.  Analysis of experimentally obtained data sets provides fits that lie within a small 
range of consistent values. This work aims to understand and identify the basis for the 
“range”. We aim to determine if the “range” is due to inherent error in experimental data 
or a consequence of attempting to simultaneously determine the best fits for all 
parameters. By fitting the experimental data we obtain the consensus fits for all 
parameters. This is used to generate perfect (no error) data via simulations, which are 
then fitted via the same technique. We find that even fitting of perfect data results in a 
range of fits rather than a lone vector of parameter values, suggesting that inherent 
experimental error may not be the “source” for the “range”. 
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Paper 1: Introduction 
 
P-glycoprotein (P-gp) is a 170 kDa transmembrane protein that is expressed in various 
tissues in humans (Arceci et al., 1988; Cordon-Cardo et al., 1989; Klimecki et al., 1994; 
Beaulieu et al., 1997; Edwards et al., 2005; Sharom, 2007). It is a member of the ATP 
binding cassette (ABC) family of proteins that has been extensively studied because of its 
ability to render cells resistant to many chemotherapeutic agents including anticancer 
drugs and antibiotics (Sharom, 2007). P-gp is known to play an important role in the 
absorption, distribution and elimination of drugs and is believed to be responsible for 
clinically important drug-drug interactions (Ambudkar et al., 1999; Tam et al., 2003). 
Several mathematical models have been employed to understand the kinetics of drug 
efflux by P-gp through confluent cell monolayer systems. Linear vectorial models 
indicate the role of P-gp in drug efflux (Ito et al., 1999; Johnson et al., 2003; Bartholome 
et al., 2007; Sun and Pang, 2008). This model may be extended to show the involvement 
of other proteins in the efflux process. It is limited, however to indicating the contribution 
of the protein as a percentage of the whole process. It cannot indicate, for example, how 
fast the drug is effluxed by the protein.  
The inherent drawback of linear models can be overcome by employing fitting routines 
that simulate nonlinear steady state Michaelis-Menten kinetic equations by employing the 
mass action model: 
 
where T0 is the empty transporter, CPC is the concentration of substrate in the cytoplasmic 
compartment, T1 is the transporter bound to substrate, and CA is the substrate after efflux 
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into the apical chamber. The mechanism of substrate efflux by the protein is described in 
terms of two numbers, the maximal rate of efflux (Vmax = k2 x T(0), where T(0) = T0 + T1) 
and the Michaelis-Menton constant (Km = (k2 + kr)/k1) (Horio et al., 1990; Ho et al., 1995; 
Stein, 1997; Doppenschmitt et al., 1999; Kuh et al., 2000; Al-Shawi et al., 2003). 
However, for membrane proteins that pick up substrate from the membrane (rather than 
the aqueous regions) itself, such as P-gp, we find that with such fitting techniques there is 
no correlation between the experimental and molecular Km value obtained from the 
elementary rate parameters. Moreover, this technique cannot predict the elementary rate 
parameters itself. The prediction of these parameters provides a better understanding of 
the structure-function relationship of the protein. 
The minimal mass action kinetic model is the only model that is capable of predicting the 
elementary kinetic parameters, by simultaneously fitting all necessary parameters 
describing drug efflux by P-gp (Tran et al., 2005; Acharya et al., 2006; Acharya et al., 
2008). It uses the same model described above, but makes use of non-steady state, rather 
than steady-state, equations. Moreover, it takes into consideration drug partitioning into 
the inner monolayer of the cell membrane, where P-gp is known to pick it up from (i.e. 
CPC for this technique is the concentration of drug in the apical inner monolayer).  This 
kinetic analysis of drug efflux by P-gp simultaneously fits any and all parameters, each 
parameter having a broad range of potential values. We shall refer to this as a “global 
optimization process.” 
One of the limitations of this technique is that it provides a small range of consensus fits 
for each and every parameter, rather than a solitary correct value (Tran et al., 2005; 
Acharya et al., 2006; Acharya et al., 2008). This work aims to examine if this range may 
 43
be attributed to the inherent error in experimental data or the global optimization fitting 
technique employed by the minimal mass action kinetic model. A simple yet effective 
way on doing this is by comparing the fits of experimental data to that obtained from 
perfect data, generated via simulations using the consensus fits from experimental data. A 
better understanding of the basis of the range will allow better extrapolation in vivo 
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Paper 1: Materials and Methods 
 
Experimental set-up: Experimental data was obtained courtesy of Acharya et. al. (2006, 
2008). Briefly, Madin-Darby Canine Kidney II cell line that overexpresses human MDR1 
(MDCKII-hMDR1) were first grown in 175 cm2 culture flasks using DMEM (MediaTech, 
VWR) with 10% fetal bovine serum, 1% L-glutamine and 50 U/mL penicillin, 50mg/mL 
streptomycin at 37ºC in 5% CO2 atmosphere. Cells were split twice a week at 70-80% 
confluency in a ratio of 1:40, after at least 2 washes in PBS and being trypsinized with 
0.25% trypsin/EDTA. 
For the single substrate efflux assay, cells were seeded in 12 well Costar-Transwell plates 
with polycarbonate membrane inserts (0.4um pore size and 12 mm diameter – Acton, 
MA) at a density of 175,000 cells per insert and grown for four days in culture medium, 
fresh medium being given the next day. Just prior to the experiment, culture media was 
removed and cells were pre-incubated for 30 minutes with either transport media alone or 
transport media with 2 µM GF120918 (GlaxoSmithKline Pharmaceuticals, USA), an 
inhibitor of P-gp. Efflux of each drug (amprenavir, quinidine, loperamide and digoxin), 
supplemented with their respective radiolabelled equivalent at  0.5 mCi/mL to allow 
quantitation of efflux from donor to receiver chambers, was measured by taking 25µl 
samples over a period of 4 – 6 hours from both the donor and receiver chambers. 
Radioactivity was counted by TopCount Model 9912 (Perkin Elmer, USA).  
To monitor the integrity of the confluent monolayer model lucifer yellow (100µM) was 
added to the donor side. Comparison of the fluorescence of lucifer yellow at time zero to 
that at the final time point, from both, the donor as well as the receiver chambers allowed 
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Acharya et al. (2006, 2008) to determine if the integrity of the monolayer was maintained. 
Fluorescence was analyzed using a SpectraMax microplate reader ((Ex max = 438nm, 
Em max = 530nm). 
Transport of drug was measured in both directions, i.e. apical to basolateral (A>B) and 
basolateral to apical (B>A). Further details may be obtained from Acharya et al. (2006, 
2008) 
 
Fitting of data sets using particle swarm: We adopt a particle swarm technique to fit our 
data sets, in order to determine the elementary rate parameters. This fitting routine is 
different from the one adopted by Tran et al. (2005) or Acharya et al. (2008). The range 
for each parameter is as follows: association rate constant (k1), 106 – 1012 M-1s-1; efflux 
rate constant (k2), 1 – 104 s-1; P-gp concentration (T(0)), 10-6 – 10-2 M; association 
constant (KC), from which the dissociation rate (kr) is determined, 102 – 106 M-1. The 
upper bounds are theoretical maxima (Tran et al., 2005). The virtue of this fitting 
technique is that we can fit all data sets simultaneously, unlike the hierarchal fitting 
technique where each data set had to be fit individually. The goal is to get the best fits for 
all parameters. The “goodness of fit” was quantified by the coefficient of variance (CV), 
which is defined as the root mean square error between the data points of a given drug 
concentration and the simulation output of MATLAB, divided by the initial substrate 
concentration for a given data set, normalized over all drugs for all concentrations.  
We first set a “baseline” CV by using an initial vector of parameter values (this is set at 0 
for all parameters), before the starting of the particle swarm. When a lower CV is 
obtained, the vector of parameter values gets saved and replaced. And this serves as the 
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new baseline. Termination of the routine occurs when a local minimum CV is detected. 
The vector of parameter values corresponding to this CV is the best fit. 
As our first step, we simultaneously fit all the data sets obtained experimentally, to obtain 
the consensus values for T(0) and k1. The other kinetic parameters were allowed to vary 
within broad ranges, as explained above. We run 20 independent replicate fits in order to 
get the range of the T(0) and k1 values. We calculated the mean value for T(0) and k1. 
In the next step, we fix the T(0) and k1 at the calculated mean value and search for the 
best fits of all other parameters, for each drug individually. In other words to get the k2 
and kr values for quinidine, we use only the quinidine data sets. Again, we run 20 
independent replicate fits in order to get the range for each parameter. Thus we obtain the 
best fits for all the elementary parameters. We calculate the mean values for all the other 
parameters as well. 
Next, we generated perfect data using simulations. The elementary parameter values used 
to generate this data are the mean of the values obtained by fitting the experimental data 
sets. We subject the simulation data to the same fitting routine. 
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Paper 1: Results 
 
Fitting the data sets: The kinetic equations used for the fitting process is as described by 
Acharya et al. (2006, 2008). Experimental data for 4 different drugs (Amprenavir, 
Quinidine, Loperamide, and Digoxin) were obtained from the same (Acharya et al., 2006). 
For each drug the number of data sets and drug concentrations were different 
(Amprenavir – 11 datasets with concentrations varying from 20 – 100µM; Quinidine – 10 
datasets with concentrations varying from 0.1 – 10µM; Loperamide – 19 datasets with 
concentrations varying from 0.03 – 30µM; and, Digoxin – 4 datasets with concentrations 
varying from 10 – 50µM). 
The data was fit using a particle swarm fitting routine, as described in the materials and 
methods. This technique is different from that adopted by Acharya et al. (2006), who 
used a two step hierarchal fitting techniques similar to Tran et al. (2005). The particle 
swarm fitting routine is a better and faster technique capable of simultaneously fitting all 
data sets. 
 
Obtaining the range for each individual parameter from experimental data: We have 
shown that T(0) and k1 values are drug independent (Tran et al., 2004; Acharya et al., 
2006). This means that the first step in the fitting algorithm simultaneously fits all the 
data sets, to obtain the consensus values for T(0) and k1. The other kinetic parameters 
were allowed to vary within broad ranges, specified in Materials and Methods.  
Fig. 1A shows the results for 20 independent replicate fits of the data, which shows the 
range of k1 and T(0) values that give essentially identical fits, i.e. the coefficients of 
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variation for each replicate fit was between 2.6e-2 and 3e-2. The x- and y-axes show the 
range that was sampled by the fitting.  The upper bounds are theoretical maxima (Tran et 
al., 2005).  T(0) values ranged within 3 orders of magnitude and k1 values ranged within 
100-fold. While this appears large, it means that the data only require that the drugs 
approach P-gp at lipid lateral diffusion control.  The mean value shown on Fig. 1A was 
chosen as the consensus values for T(0) and k1, shown in Table 1. The fits for the other 
kinetic parameters ranged widely in response to the particular values of T(0) and k1 
shown in Fig. 1A (not shown).  They will be refitted using the consensus values of T(0) 
and k1.   
Figure 1B shows the ranges for binding constant (KC = k1/kr) and k2T(0), for each 
particular values of the kinetic parameters obtained by simultaneously fitting all the data 
sets. The upper bounds, again, are theoretical maxima (Tran et al., 2005) The values for 
both, KC as well as k2T(0), ranged within 10 fold. The greatest ranges were obtained for 
digoxin. 
For determining the k2 and kr values for the individual drugs, we fixed T(0) and k1 values 
at the consensus value indicated in table 1. k2 and kr could then take any value within the 
theoretical range defined by Tran et al. (2005).  
We found that k2 could be determined within 2 orders of magnitude, whereas kr values 
were always found within a 10 fold range (data not included). Although the range for kr 
may seem big, one must keep in mind that for the various drugs tested, kr is expected to 
be large. For a multidrug resistance protein such as P-gp, it is important to maintain a 
relatively low binding to be able to efflux a large variety of compounds. Since k1 is a big 
number, it is important for kr to be big as well. Weather this is 103 or 105 has little 
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consequence to the efflux kinetics. What is important to note is that the best fits gave a 
large, but closed set of kr values despite the large range of values (1 – 1010 s-1) that it 
could take. 
As with the case of the KC vs. k2T(0) fits, we find that the greatest ranges are obtained for 
digoxin. The results of the kinetic parameter values obtained have been summarized in 
table 1. 
 
Obtaining the range for each individual parameter by fitting simulations with no error: 
Based on the values obtained from the fits of experimental data, we generated perfect 
data (no error). This was done via simulations. If experimental error is the cause for the 
“spread” in determining the primary efflux parameters and P-gp concentrations, then 
fitting this data would get rid of the spread, i.e. we should get the same vector of values 
every time we fit the data. The same fitting routine was followed as with the experimental 
data, i.e. we determined T(0) and k1 first, followed by k2 and kr.  
Fig. 1C shows this range for T(0) and k1. These are the results of 20 independent replicate 
fits of data. The coefficient of variation of each replicate fit was between 4e-4 and 6e-3, i.e. 
the fits were essentially similar. The x- and y-axes show the theoretical range sampled by 
the fitting (Tran et al., 2005). The range for the T(0) and k1 values obtained here are 
similar to that obtained by fitting experimental data. T(0) values ranged within 3 orders 
of magnitude and k1 values ranged within 100-fold. The mean value shown on Fig. 1C 
was chosen as the consensus values for T(0) and k1, shown in Table 1 (within 
parenthesis). Filled (larger) symbols indicate the “simulation parameter” used to generate 
perfect data. As the figure indicates, the mean value is similar to the simulation value, 
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which is an indication of the strength of the fit. Once again, the fits for the other kinetic 
parameters ranged widely in response to the particular values of T(0) and k1 shown in Fig. 
1C (not shown). 
Fig. 1D shows the range obtained for KC and k2T(0). The filled icon indicates the value of 
the simulation parameter used to generate the data. Again, the results are similar to that 
obtained by fitting experimental data i.e., the values for both, KC as well as k2T(0), 
ranged within 10 fold .  
Fig. 2 shows the fits obtained for k2 and kr, obtained by keeping the T(0) and k1 fixed at 
the consensus value indicated. The filled icon indicates the value of the simulation 
parameter used to generate the data. As was the case with the experimental data, we 
found that k2 could be determined within 2 orders of magnitude, whereas kr values were 
always found within a 10 fold range.  
Thus we find that even when fitting perfect data, we get the range similar to that obtained 
by fitting experimental data. We did not get a lone vector of parameter values, i.e. every 
time the fitting was done, we got a different vector of parameter values resulting in a 
range for each parameter. This clearly shows that error is not responsible for the range 
obtained. 
 
Effect of changing T(0) and k1 on the fitting surface: As Tran et al. (2005) pointed out a 
multi-variable parameter fitting routine, like the one we employ, results in a fitting 
surface with several peaks and troughs. We try to find the “deepest valley” (best fit) in 
this fitting surface. In order to eliminate the possibility that error affects the range of fits, 
we need to understand how it changes the fitting surface. In other words, if error 
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considerably “flattens” the “deepest valley”, we can rightfully say that it results in greater 
ranges of fits. 
Our fitting routine attempts to determine at least 4 parameters (k1, k2, kr, and T(0)). Since 
it is difficult to visualize the effect of simultaneously changing all four parameters, on the 
fitting surface, we choose to change only two parameters. T(0) and k1 are the two 
parameters that are the same for all drugs and were thus chosen. In addition, to see if the 
effect is different for different drugs, we look at the fitting surfaces for quinidine and 
digoxin, separately. 
We find that whether the data is experimental (figs. 3A and 3B) or perfect (figs. 3C and 
3D), we get a closed set of T(0) and k1 values that describe the best fits (lowest CVs), i.e. 
the fitting surfaces are similar. Experimental error does not “flatten” the surface 
considerably; the ranges obtained from fits of experimental data lie within 2 orders of 
magnitude of fits of simulated data. A comparison of the fitting surface of quinidine 
(figs.3A and 3C) and digoxin (figs. 3B and 3D) shows that digoxin has a slightly larger 
range of best fits than quinidine, even for perfect data. Acharya et al. (2006) showed that 
the efflux of digoxin involves additional transporters in the apical and basolateral sides. 
We take this into account in  the fitting routine. Thus, when fitting digoxin data, besides 
determining the 4 parameters for P-gp, we also attempt to determine the Vmax values for 
the additional transporters involved (Km for these transporters is fixed at 100 µM). The 
fitting surface for digoxin being flatter than quinidine may suggest that the range may be 
influenced by the number of efflux parameters that needs to be fitted/determined. 
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Paper 1: Discussion 
 
The distinctive advantage of employing the minimal mass action model over traditional 
methods used for kinetic analyses of P-gp, such as linear compartmental analysis or the 
steady state Michaelis-Menten kinetic analysis, is clear. Determining the elementary rate 
parameters provides a better structure-function relationship for P-gp. 
One of the distinct limitations of the minimal mass action model is that it gives a small 
range of values for each parameter, rather than a lone vector of fits. The “goodness of fit” 
is quantified by the coefficient of variance (CV), which is defined as the root mean 
square error between the data points of a given drug concentration and the simulation 
output of MATLAB, divided by the initial substrate concentration for a given data set 
(Tran et al., 2005). The CV of each fit is similar, i.e. any value that a parameter can take 
fits the data as well as any other value, within the specified range. In order to effectively 
extrapolate this model in vivo, we need to understand the underlying reason behind this 
range. This may either be attributed to (1) inherent error in the experimental data, or, (2) 
attempting to simultaneously obtain the best fits of several parameters, i.e., globally 
optimizing the fit. 
While it is clear that experimental error can influence the fits, thus resulting in a range of 
values, why should global optimization cause the same? We shall attempt to explain this 
with a simple example: 
Let us assume that we are able to relate two variables by the simple equation defining a 
line, i.e. y = m.x + c, where the parameter “m” is the slope of the line, and “c” the 
intercept. Thus by fitting the y vs. x data, we can easily determine our parameters. Now 
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suppose both “m” and “c” are further composed of elementary parameters; for example, 
let us say that: 
m = (m1 + m2)/m3, and, 
      c = c1 . c2 
We can easily see that there are several values that the elementary parameters (m1, m2, m3, 
and, c1 and c2) can take that will satisfy for “m” and “c” , and hence the relationship 
between y and x. Thus if we attempted to fit y vs. x data to obtain the elementary 
parameters, we may get a range for each parameter, rather than a lone vector of fits. A 
similar concept may be extended to the minimal mass action model. 
A comparison of the values obtained by fitting experimental data to that obtained by 
fitting data generated by simulation (perfect data), clearly shows the ranges are similar, 
for each and every parameter being fitted. Even when the data has no error, we still get a 
range of possible fits, rather than a solitary vector of correct values. This indicates that 
error is not responsible for the “range” obtained. To further confirm that error does not 
influence the range of fits, we chose to fit a single simulation data set, for one drug 
several times. This eliminates the possibility of error completely. Plus, since only one 
data set is being fitted, we should get the same vector of values for every fit. We chose to 
fit simulation data of quinidine at a concentration of 3µM. Each consensus fit gave a 
different vector of parameter values thus, still, resulting in a range within which each 
individual parameter may lie (data not included). This clearly shows that error does not 
influence the range of fits. 
How relevant is this range? We find a 100 fold range for k1 and a 10 fold range for kr. 
However, the binding constant KC (k1/kr) was always rigorously fitted (within a 2–3 fold 
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range), and was always a small number. This number, KC, is important because it is a 
measure of the efficacy of the interaction between the drug and P-gp in vivo. It being 
small suggests that P-gp is able to interact with several, structurally different drug 
molecules, an important requirement for a multidrug resistance transporter. Thus a k1 
value of 109 M-1s-1 or 107 M-1s-1, rather than 108 M-1s-1, or a kr value of 103s-1 or 105s-1, 
rather than 104s-1, has little overall impact on the efflux process, as long as KC is 
rigorously fitted. The range of values for T(0) and k2 are small (within 2 – 3 fold) and this 
is important because large changes in these values can dramatically affect drug efflux. 
It is important to point out that the range of values obtained by fitting digoxin data was 
always found to be slightly larger than those obtained by fitting the data of any other drug. 
As we pointed out earlier, to appropriately explain the kinetics of digoxin efflux, we need 
to determine additional parameters corresponding to the additional transporters present on  
the apical and basolateral membranes (Acharya et al., 2008). It is possible that as the 
number of parameters to be determined increases, the range of each individual parameter 
increases as well. We believe this is what our results indicate. 
Another important contribution of this work is the introduction of a particle swarm fitting 
technique to determine the elementary parameters. Both Tran et al. (2005) and Acharya et 
al. (2008) used a hierarchal fitting technique to fit the parameters. In this technique the 
“forward” apical to basolateral (B>A) data is first fit using the forward parameters T(0), 
k1, and k2. This reduces the ranges for T(0), k1, and k2. The “reverse” basolateral to apical 
(A>B) data is fit next with the reduced range, to obtain the various parameters, including 
kr. This helped to reduce the time required for data fitting (Tran et al., 2005). The fitting 
was also done stepwise, starting with a “coarse fit” (broad range of values, low tolerance) 
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and ending with a “fine fit” (small range, high tolerance), which gave the final range for 
each parameter.  
One of the major limitations of the two-step hierarchal fitting technique is that it required 
7 – 9 days on a 2.8 GHz PC to complete the fit for one drug concentration (Tran et al., 
2004.). So to fit data for 4 different drugs, each with 8 different concentrations would 
require ~7 – 10 months.  
The particle swarm technique fits data obtained by studying transport in both directions 
simultaneously, starting with the original broad range, covering all possible biologically 
relevant values, and a high tolerance. This technique allows the computation of best fits, 
while simultaneously fitting all datasets, within 4 days. Thus by employing the particle 
swarm technique, we have made it considerably easier, and faster to use the minimal 
mass action model. 
In retrospect, in order to be able to optimally extrapolate any kinetic model from in vitro 
to in vivo systems, one must understand all limitations and results of the model. Here in 
lies the importance of this study. We have clearly and completely dissected why our 
model provides a range of parameter fits, and conclude that the range is a result of 
attempting to determine several parameters simultaneously rather than inherent error in 
the data.  
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Paper 1: Tables 
 
 
 
 
 
Table 1: Paper 1, Table 1: Parameter estimates obtained by fitting of experimental and 
simulated (within parenthesis) data   
Substrate 
Efflux active P-gp 
density 
T(0)a µM 
Association 
to P-gp 
k1b (M-1s-1)
Efflux to 
apical 
chamber 
k2c (s-1) 
Dissociation 
to P-gp 
krd (s-1) 
Binding 
constant 
KCe (M-1) 
“Vmax” 
k2 T(0)f 
(Ms-1) 
AMP 
500 
(400) 
5 x 107 
(5 x 107) 
60 
(60) 
7 x 104 
(7 x 104) 
7 x 102 
(7 x 102) 
3 x 10-2 
(2 x 10-2)
QND 
500 
(400) 
5 x 107 
(5 x 107) 
4 
(4) 
4 x 103 
(4 x 103) 
1 x 104 
(1 x 104) 
2 x 10-3 
(2 x 10-3)
LPM 
500 
(400) 
5 x 107 
(5 x 107) 
0.7 
(0.7) 
2 x 104 
(2 x 104) 
3 x 103 
(3 x 103) 
3 x 10-4 
(3 x 10-4)
DGX 
500 
(400) 
5 x 107 
(5 x 107) 
6 
(10) 
2 x 104 
(7 x 104) 
3 x 103 
(7 x 102) 
3 x 10-3 
(4 x 10-3)
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Legend for Table 1 
 
a The efflux-active concentration of P-gp within the inner apical monolayer obtained 
from the average of the log values of the fits. These units can be converted to a more 
typical form, assuming a 2 nm lipid monolayer thickness for the acyl chain region. T(0) 
(P-gp/µm2) =0.8T(0) (µM, inner apical monolayer) 400 P-gp/µm2. The ratio of the apical 
membrane to the insert cross-section area is irrelevant, because it cancels out in the 
calculation. 
b The estimate for the association rate constant k1, obtained from the average of the log 
values of the fits. 
c The efflux rate constant k2, from P-gp into the apical chamber, obtained from the 
average of the log values of the fits 
d The dissociation rate constant kr, from P-gp back into the inner apical monolayer, 
obtained from the average of the log values of the fits. 
e KC is calculated as k1/kr. 
f k2T(0) is the product of k2 and T(0) shown. 
 61
Paper 1: Figure Legends 
 
Figure 1: Ranges of values of various parameters indicated obtained by fitting both 
experimental, as well as simulation data: Plots showing the ranges of T(0) and k1 (figs. 
1A and 1C), and, KC and k2T(0) (figs. 1B and 1D). “Experimental” denotes the parameter 
ranges obtained by fitting the experimental data from Acharya et al. (2006, 2008); 
“Simulation” denotes the parameter ranges obtained by fitting curves simulated from the 
parameters shown in Table 1 without any error. Fits were done for 4 drugs (Amprenavir, 
AMP; Quinidine, QND; Loperamide, LPM; and Digoxin, DGX) as indicated. For the 
experimental data, T(0) values ranged within 3 orders of magnitude and k1 values ranged 
within 100-fold (fig. 1A) while both, KC as well as k2T(0) values, show ranges within 10 
fold (fig. 1B). Similar ranges were seen by fitting simulation values (figs. 1C and 1D). 
The fits did not give a solitary, correct value for any of the parameters even for the 
simulations, which had no error. The mean value shown in figures 1A and 1C are the 
consensus values for T(0) and k1, from all fits. Filled (larger) symbols indicate the 
“simulation parameter” used to generate simulation data 
 
Figure 2: Ranges of k2 and kr values obtained by fitting simulation data: Plots 
showing the ranges for k2 and kr obtained by fitting simulations with 0% error. Since 
these parameters are drug dependent, values for each drug is shown separately. T(0) and 
k1 values were fixed to values shown in Table 1. Irrespective of the drug, the k2 values 
does not vary more than 2 fold while the kr does not vary more than 10 fold. The 
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maximum range is seen for digoxin (DGX). Filled symbols indicate the “simulation 
parameter” value used to generate simulation data. 
 
Figure 3: Effect of varying T(0) and k1 values only: Effect of changing T(0) and k1 on 
the coefficient of variance (CV) of fits for quinidine and digoxin, with the other kinetic 
parameters held constant.  “Experimental” denotes the fitting surface obtained by fitting 
the experimental data (figs. 3A and 3B); “Simulation” represents that obtained by fitting 
simulations with 0% error (figs. 3C and 3D). We get a closed range of values irrespective 
of data (experimental or simulation) set considered.  Experimental error affects only the 
coefficient of variance of fits, with little effect on the range. The fitting surface for 
digoxin (DGX) appears to be “flatter” than that of quinidine (QND) suggesting that the 
number of parameters that need to be determined may affect the fitting surface. 
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Figure 1: Paper 1, Figure 1: Ranges of values of various parameters indicated obtained by 
fitting both experimental, as well as simulation data 
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Figure 2: Paper 1, Figure 2: Ranges of k2 and kr values obtained by fitting simulation data 
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Figure 3: Paper 1, Figure 3: Effect of varying T(0) and k1 values only 
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Eadie-Hofstee plots of the fitted parameters of either model; Vmax_SS, Vmax measured by 
the steady state compartmental model; Vmax_MA, Vmax measured by the minimal mass 
action model; Km(mol), Molecular Km value as predicted by the elementary mass-action 
kinetic parameters; Km(EH), Km obtained from the Eadie-Hofstee plots of the fitted 
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parameters of either model; Km_SS, Km measured by the steady state compartmental 
model; Km_MA, Km measured by the minimal mass action model 
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Paper 2: Abstract 
 
Mass action models of trans-cellular transport have been shown to be effective to 
understand drug efflux kinetics by membrane transporters, such as the multidrug efflux 
protein P-glycoprotein (P-gp). The fits obtained from the simulations can predict the 
Michaelis-Menten kinetic parameters Vmax, the maximal rate of drug efflux, and Km, the 
substrate concentration at which the efflux velocity is half the maximal rate. The question 
is the extent to which Vmax and Km obtained from the simulations correlate to their 
molecular values as predicted by the elementary mass-action kinetic parameters. Bentz et 
al. (2005) fitted model data generated by using the minimal mass action model of drug 
efflux via P-gp expressed in a confluent cell monolayer, and fitting this data to an Eadie-
Hofstee plot, to show that the “experimental” Vmax, obtained via simulations, roughly 
correlates with its molecular value in the steady state.  However, the “experimental” Km 
did not correlate with its molecular value. An experimentally measured Km could arise 
from molecular Km values ranging over several orders of magnitude. Recently, Sun and 
Pang (2008) employing a comparable nonlinear steady state simulation technique to 
generate data, obtained the opposite result:  the Vmax’s did not correlate, but the Km’s did.  
The purpose of this study is to compare and contrast the two computational models in 
their abilities to determine the kinetic parameters and to examine the possible reason for 
the discrepancies in correlations obtained by the same. Using simulations based on both 
models data for drug efflux was generated. “Experimental” Vmax and Km were determined, 
by fitting to an Eadie-Hofstee plot, and compared to the molecular values. Our results 
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indicate that the correlations seen by employing either model is the same, provided that 
the right substrate concentrations are used.  
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Paper 2: Introduction 
 
Modeling techniques have often been used to examine the role of proteins in the transport 
of substances. The simplest model that has often been employed is the linear 
compartmental model. In this technique, the “efflux ratio” (the ratio of the rate of 
transport from basolateral to apical chamber to the rate of transport from the apical to 
basolateral chamber), when the protein is active/inactive, is determined. If the efflux ratio 
is altered when the protein is active, then the involvement of the protein in the process is 
justified (Anderson, 1983). Earliest examples employing this technique include the study 
of cation exchange between erythrocytes and plasma (Sheppard and Martin, 1950) as 
well as digestion and uptake of food in sheep (Blaxter et al., 1956). The limitation of this 
model lies in its inability to explain the full extent of the involvement of the protein. It is 
unable to determine, for example, the rate at which the protein transports the substance. 
This drawback is overcome via the nonlinear compartmental modeling technique 
(Anderson, 1983; Ito et al., 1999; Sun and Pang, 2008). This techniques for example, can, 
under steady state conditions, determine the rate at which the protein transports 
substances (Vmax) as well as the Michaelis-Menten rate constant (Km) thus giving a better 
understanding of the function of the protein to the efflux process. However, these values 
cannot be successfully correlated to the structure of the protein. 
The advent of faster computers allowed explorations of more complex models giving a 
better understanding of the transport mechanism employed by the protein. One such 
model is the minimal mass action kinetic model (Tran et al., 2004; Bentz et al., 2005; 
Tran et al., 2005; Acharya et al., 2006). This model is capable of predicting the 
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elementary rate parameters that constitute Vmax and Km by performing a non-steady state 
kinetic analysis, thus providing a better structure-function relationship for the protein 
involved. 
A widely studied membrane protein employing the above mathematical models is P-
glycoprotein (P-gp), a multidrug resistance protein that has been investigated due to its 
implication in rendering cells resistant to a variety of xenobiotics including anticancer 
drugs and antibiotics (Borst and Elferink, 2002; Gottesman, 2002; Poelarends et al., 2002; 
Ambudkar et al., 2003). Simple linear models (Ito et al., 1999; Sun and Pang, 2008), 
nonlinear steady state models (Demant et al., 1990; Ashida et al., 1998; Tam et al., 2003; 
Irie et al., 2004; Gonzalez-Alvarez et al., 2005; Sun and Pang, 2008) as well as the 
minimal mass action model (Tran et al., 2004; Bentz et al., 2005; Tran et al., 2005; 
Acharya et al., 2006) provide valuable insight into the transport process employed by the 
protein. These findings are further complimented by mutational studies  (Gottesman and 
Pastan, 1993; Senior et al., 1995; Ambudkar et al., 1999; Loo and Clarke, 2000; Loo and 
Clarke, 2001; Ambudkar et al., 2003; Loo and Clarke, 2005). 
Although the efficacy of the various mathematical models is well established, one needs 
to understand the extent to which Vmax and Km obtained from the simulations correlate to 
their molecular values as predicted by the elementary mass-action kinetic parameters. 
Bentz et al. (2005) used the minimal mass action kinetic model, i.e. the elementary rate 
parameters, to generate “experimental” data via simulations. They then fit this data to an 
Eadie-Hofstee plot. They showed that “experimentally” determined Vmax values 
correlates reasonably well with the molecular Vmax. However, they found no correlation 
between the molecular and experimental Km values, even if the data had no error (Bentz 
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et al., 2005). Recently, Sun and Pang (2008), using simulations of nonlinear steady state 
transport to generate “experimental” data, obtained the exact opposite result. This was 
puzzling since a Vmax depends only upon P-gp density in the membrane and the efflux 
rate constant.  One would expect the experimental Vmax to correlate with its molecular 
value regardless of the model used to simulate P-gp efflux.  
Thus the objective of this study is to compare and contrast the two computational models 
in their abilities to determine the kinetic parameters and to examine the possible reason 
for the discrepancies in correlations obtained by the same. 
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Paper 2: Materials and Methods 
 
Figure 1 is a generic figure exhibiting drug efflux via both models. It indicates the 
passive permeability barriers/rates as well as the active efflux by P-gp for each model. A 
comparison of the steady state and minimal mass action models yields the following 
relations: 
AOmax_MAmax_SS .VVV = ;  
PC
m_MA
m_SS K
K
K =  
Where, Vmax_SS and Vmax_MA are the maximal drug efflux velocities, and Km_SS and Km_MA 
are the Michaelis-Menten constants, for the steady state (SS) and minimal mass action 
(MA) models, respectively. VAO (= 0.5nl) is the volume of the apical outer monolayer 
and, KPC (= 710) is the equilibrium partition coefficient of the drug to the plasma 
cytoplasmic monolayer. The equations used to derive these relations; the other 
parameters used (and their values) have been described in the supplementary material.  
We aim to compare and contrast the steady state compartmental model and the minimal 
mass action model for all ranges of parameter values previously tested by Sun and Pang 
(2008) and Bentz et al. (2005) to understand the reason for the differences in results 
obtained by the two models. Passive drug clearance rates (product of passive 
permeability coefficient, P in nm/s, and membrane area, A in cm2) varying from 10-4 – 1 
ml/min were tested. Clearance rates across both membranes in either direction were 
assumed to be equal. Vmax(mol) was varied from 0.15 – 1500 µM/hr (0.01 – 100 nmol/min, 
assuming total volume to be 4 ml) and Km(mol) was varied from 0.01 – 100 µM. This 
encompasses all ranges tested by both Sun and Pang (2008) as well as Bentz et al. 
(2005).We ignored the possibility of loss and/or metabolism of drug, as a simplification. 
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Based on a given set of clearance, Vmax(mol), and, Km(mol) values we generated “drug efflux 
data”, using either the steady state Michaelis-Menten model, or the minimal mass action 
model, at 6 different substrate concentrations. The highest substrate concentration was 
appropriately chosen so as to allow P-gp saturation of ≥ 70%. From the efflux data 
generated, the two hour time point was chosen to determine the efflux velocity, V, at the 
given substrate concentration. The Eadie-Hofstee plot for the given condition was then 
generated. 
We used the stiffest integrator in MATLAB, ode23s (The MathWorks, Natick, MA) for 
our simulations. The tolerance levels used in the simulations dictated the time required 
for the MATLAB subroutine, fminsearch, to find the local minimum. We used a 
tolerance level of 10-8, which was found to be an adequate compromise between speed 
and accuracy  (Tran et al., 2004; Bentz et al., 2005; Tran et al., 2005; Acharya et al., 2006) 
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Paper 2: Results 
 
Range of values of each parameter used to generate simulation data: Typical passive 
permeability coefficient values range from 2 – 850 nm/s (Doan et al., 2002).  If we 
assume an apical membrane area of 2.26 cm2 (Tran et al., 2004; Tran et al., 2005; 
Acharya et al., 2006; Acharya et al., 2008), then drug clearance would range from 3e-5 – 
1.4e-2 ml/min. Vmax values for various drugs ranging from 0.5 – 100 µM/hr, and Km 
values ranging from 0.01 – 100 µM, have been reported (Hunter et al., 1993; Adachi et 
al., 2001; Stephens et al., 2001; Tang et al., 2002a; Tang et al., 2002b; Troutman and 
Thakker, 2003a; Collett et al., 2004; Tran et al., 2005; Acharya et al., 2006; Acharya et 
al., 2008). Assuming a total volume of 4 ml (1.5 ml for the apical chamber and 2.5 ml for 
the basolateral chamber (Sun and Pang, 2008), we get a Vmax range of 0.03 – 7 nmol/min. 
The reported parameter values form the basis for our “physiological range”.  The range of 
values tested by Bentz et al. (2005) is encompassed in those tested by Sun and Pang 
(2008). Thus, to generate simulation (“experimental”) data, we use molecular Vmax and 
Km ranges similar to Sun and Pang (2008). However drug clearance rates varied from 1e-4 
– 1 ml/min to match conditions simulated by both Bentz et al (2005) as well as Sun and 
Pang (2008). 
 
Curvature of Eadie-Hofstee plots: Figure 2 represents a sample Eadie-Hofstee plot 
created to determine the Vmax from simulations (i.e., Vmax(EH)). The steady state 
Michaelis-Menten model was used to simulate the efflux. For the simulation, we fixed 
Vmax(mol) at 30µM/hr, Km(mol) at 0.1µM, and drug clearance rate at 0.01 ml/min. The 
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sample shows B>A transport for drug concentrations at 10, 30, 50, 70, 100 and 130µM. 
We chose the 2 hr time point to determine V. A similar Eadie-Hofstee plot was obtained 
when the minimal mass action model was used to simulate efflux. 
Since the plot is curved, only the highest substrate concentrations must be used to 
determine Vmax. A linear regression of all data points overestimates Vmax. Similarly, if the 
substrate concentration is too low (less than 70% P-gp saturation), Vmax is overestimated. 
This is consistent with results stated elsewhere (Bentz et al., 2005; Sun and Pang, 2008). 
For our fitting routines, we choose substrate concentrations that are required to saturate 
P-gp by 75%. We refer to this as S(0). 
We found that in order to determine the right Vmax(EH) (and hence correct Km(EH)) values, 
S(0) had to be in the molar range for some of the conditions tested (data not included). 
Although this is not physiologically relevant, it was necessary to simulate with such high 
S(0) values, to examine the correlation between the molecular and fitted values, over all 
parameter ranges tested in earlier studies (Bentz et al., 2005; Sun and Pang, 2008). This 
would allow us to confirm if both models, the steady-state Michaelis-Menten model, and 
the minimal mass action model, generated similar results, or different ones, as reported 
by Sun and Pang (2008), while simultaneously avoiding any discrepancies that may have 
been there due to different parameter ranges tested (Bentz et al., 2005; Sun and Pang, 
2008). It is important to point out that such high S(0) values were required for generating 
data to emulate conditions when clearance was low, but Vmax(mol) was >50µM/hr. 
 
Correlation between Vmax(EH) and Vmax(mol): Figures 3 shows the correlation between 
Vmax(EH) and Vmax(mol) obtained from simulations of the steady state model, at 5 different 
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clearance rates tested. Open symbols represent the correlation obtained by fitting the 
A>B data while closed symbols represent the correlation obtained by fitting the B>A data. 
Enclosed (boxed) area indicates the correlation at physiologically relevant ranges. 
Simulations of the minimal mass action model show the same results (not included). 
We find that at a given clearance rate there is a logarithmic correlation between Vmax(EH) 
and Vmax(mol) (fig. 3A). Although the correlation appears to be sensitive to the direction of 
drug transport (especially at the lower clearances), this disappears when 5 – 10% error is 
added to the data (results not included). 
On closer examination, we found that at lower clearances (≤1e-3 ml/min), Vmax(EH) was 
equal to Vmax(mol), i.e. Vmax(mol)/Vmax(EH) ≈ 1 (fig. 3B).  However, at larger clearances, the 
“estimated” Vmax(EH) values were found to be lesser than Vmax(mol), with Vmax(EH) being up 
to 1000 times smaller than Vmax(mol), at a clearance of 1 ml/min (fig. 3B). Similar results 
are seen for data with error (2%, 5% and 10%; data not included). 
 
Lack of correlation between Km(EH) and Km(mol): Figures 4 shows the correlation between 
Km(EH) and Km(mol) obtained from simulations of the steady state model, at 5 different 
clearance rates tested. Again, open symbols represent the correlation obtained by fitting 
the A>B data while closed symbols represent the correlation obtained by fitting the B>A 
data. Simulations of the minimal mass action model show the same results (not included). 
We find that although the “expected” Km(mol) varied from 1e-2 – 1e2 µM, the “measured” 
Km(EH) varied from 1e-2 – 1e6 µM. Unlike the relationship between Vmax(EH) and Vmax(mol), 
no correlation was seen between Km(EH) and Km(mol) (fig. 4A). For any “experimentally 
measured” Km(EH), Km((mol) could vary widely, depending on clearance (fig. 4B). For 
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example, at a clearance of 0.01 ml/min, if the “measured” Km(EH) is  1µM, Km(mol) could 
vary from 0.01 – 10 µM. This basically means that it will not be possible to determine the 
Km(mol) value based on the “experimentally measured” Km(EH) value.  
However, we found that we could correlate Km(EH) and Km(mol) by a family of curves 
defined by Vmax(mol)/clearance, i.e., at a specific Vmax(mol)/clearance value, there appears to 
be some correlation between Km(EH) and Km(mol)  (data not included).  
 
Relationship between S(0), Km(mol), Km(EH), Vmax(mol) and Vmax(EH): We attempted to find a 
relationship between the molecular values, experimental values and S(0). Figure 5 shows 
the correlation between the various parameters indicated. This was obtained by 
simulating the steady state Michaelis-Menten model. Filled markers indicate the 
relationship from physiologically relevant values of Vmax, Km, and clearances as 
published by others. Similar results were obtained on simulating the minimal mass action 
model (not included). 
Fig. 5A shows the correlation between S(0), drug clearance rate, Vmax(mol) and, Km(mol). 
We find that till a Vmax(mol)/(Clearance x Km(mol)) value of 10/ml, S(0)/Km(mol) remains 
unchanged, and then logarithmically increases (fig. 5A). On a closer examination of this 
relationship, found that S(0) remained unchanged with increasing Vmax((mol)/Clearance as 
long as Km(mol) is ≥ (10 x Vmax(mol)/Clearance) (in µM/ml). In other words if Km(mol) was 1 
µM, then as long as Vmax(mol)/Clearance) ≤ 10µM/ml, S(0) did not change. Above this 
value, S(0) increased logarithmically with Vmax(mol)/Clearance (data not included).  
Fig. 5B shows the correlation between the drug clearance rate, Vmax(mol), Km(mol), Vmax(EH) 
and, Km(EH). Data for drug clearance rates of 1e-4 – 1e-2 ml/min have been shown.  Data 
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for higher drug clearances showed similar trends, but were found to be just below the 
data shown. These have not been shown since they are not biologically relevant. 
As shown in fig. 5B, we find that Vmax(EH)/(Clearance x Km(EH)) logarithmically increases 
with increasing Vmax(mol)/(Clearance x Km(mol)) till Vmax(mol)/(Clearance x Km(mol)) reaches a 
value of 10/ml and then remains unchanged. On closer examination, we found that 
Vmax(EH)/ (Clearance x Km(EH)) logarithmically increases with increasing Vmax((mol)/ 
(Clearance x Km(mol)) as long as Km(mol) ≥ (10 x Vmax(mol)/Clearance), and remained 
unchanged beyond this value (data not included). 
Although complex, there appears to be some correlation between S(0), Km(mol), Km(EH), 
Vmax(mol) and Vmax(EH). 
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Paper 2: Discussion 
 
The clinical and biological importance of P-gp has been well established. It is known to 
play an important role in the absorption, distribution and elimination of drugs and may be 
clinically important for drug-drug interactions (Lown et al., 1997; Goh et al., 2002). In 
order to elucidate its mechanism of action, appropriate kinetic models have been 
employed. Steady-state Michaelis-Menten kinetics has often been employed to explain 
the catalytic action of P-gp (Stein et al., 1994; Ho et al., 1995; Doppenschmitt et al., 1999; 
Kuh et al., 2000; Al-Shawi et al., 2003; Sun and Pang, 2008). It is assumed that the 
experimentally measured values correlate reasonably well with the molecular values 
defined by the elementary rate constants of the transporter reaction, according to the 
classical Michaelis-Menten derivation. Only with the development of the minimal mass 
action model (Tran et al., 2004; Bentz et al., 2005; Acharya et al., 2006; Acharya et al., 
2008), which determines these elementary rate constants, was it possible to investigate if 
this implicit precept were true.   
Bentz et al. (2005), via simulations that employ the minimal mass action model, showed 
that while the molecular Vmax correlates reasonably well with the “experimentally 
measured” value, the Km does not. Recently, Sun and Pang (2008), by employing 
simulations that use the steady state Michaelis-Menten equations indicated that the 
experimental Km value correlates to molecular Km, while the Vmax values do not; a result 
opposite to that seen by Bentz et al. (2005) 
We investigated the correlation between the molecular values of the steady state 
Michaelis-Menten parameters and those determined “experimentally”, by employing both 
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computational models. Our focus was to address the contrasting results observed between 
the two computational models (Bentz et al., 2005; Sun and Pang, 2008). It is our 
contention that the substrate concentration used to determine the steady-state parameters 
were too low to allow P-gp saturation for the passive permeabilities tested by Sun and 
Pang (2008), thereby resulting in an overestimation of Vmax(EH). This unmet condition, not 
cellular or simulation differences resulted in discrepancies between the two models.  
On the onset, we agree with Sun and Pang (2008) that a two-barrier model is appropriate 
model to study drug efflux kinetics of membrane proteins. We would like to clarify that 
all previous studies employing the minimal mass action model (Bentz et al., 2005; Tran et 
al., 2005; Acharya et al., 2006) have utilized a two-barrier approach. Our methodology 
has been depicted in figure 1 (passive transport). 
Our study finds that when appropriate S(0) are used there is a correlation between Vmax(EH)  
and Vmax(mol), regardless of the model employed to generate data. The correlation is best 
at low drug clearances and degrades as the clearance increases, with Vmax(EH) becoming 
progressively smaller. What could be the reason for Vmax(EH) decreasing with increasing 
clearance? Bentz et al. (2005) had shown earlier that when considering the steady state 
equations, the passive permeability coefficient gets convoluted in the Vmax parameter.  It 
is thus possible that as the clearance increases, experimentally measured Vmax(EH) value 
would decrease.  
No such correlation is seen between Km(mol) and Km(EH). The determination of an accurate 
Km value is important to understand the efficacy of the drug in vivo.  However, due to a 
lack of correlation, two drugs with the same Km(mol) for a given cell line may have very 
different values in vivo (Bentz et al., 2005).  
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We did find that Km(EH) could be correlated to Km(mol) by a family of curves defined by 
Vmax(mol)/clearance. Sun and Pang  (2008) found that at a specific pair of defined Vmax(mol)  
and clearance values, Km(mol) could be correlated to Km(EH). Our finding is similar to theirs. 
This may also be considered equivalent to the findings by Bentz et al. (2005), where the 
authors could correlate Km(EH) to Km(mol) by a family of curves defined by the product of 
the partition coefficient and binding constant. However, only model data was used for our 
simulations. Earlier testing of the minimal mass action model has shown that  the 
relationship between Km(mol) and Km(EH) blurs when data has 5% error in it (Bentz et al., 
2005) It is imperative to point out that in order to determine the highest Vmax(EH) at the 
lowest clearance accurately, simulations indicate that a substrate concentration as high as 
1.5 M is required. Although such high substrate concentrations may be physiologically 
irrelevant, the simulations clearly show that it is required for correct Vmax(EH) 
determination. However, as we pointed out earlier, these high S(0) values were required 
to simulate conditions that have not been physiologically observed. Lower substrate 
concentrations (10 – 500 µM), as used by Sun and Pang (2008) to simulate such 
conditions, result in an overestimation of Vmax(EH) for the clearances tested. Thus they 
were unable to identify a correlation between Vmax(EH) and Vmax(mol). 
We also attempt to define a relationship between the molecular and experimentally 
measured Vmax and Km values, and S(0). Our data indicates a complex relationship 
between these values. On a closer examination of the relationship of S(0)/Km(mol) vs. 
Vmax(mol)/ (Clearance x Km(mol)) we found that S(0) remained unchanged with increasing 
Vmax(mol)/Clearance as long as Km(mol) is ≥ (10 x Vmax(mol)/Clearance) (in µM/ml). In other 
words if Km(mol) was 1 µM, then as long as Vmax(mol)/Clearance) ≤ 10µM/ml, S(0) did not 
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change. Above this value, S(0) increased logarithmically with Vmax(mol)/Clearance (data 
not included). Complimentary to this relationship, we also found  that Vmax(EH)/ 
(Clearance x Km(EH)) logarithmically increases with increasing Vmax(mol)/ (Clearance x 
Km(mol)) as long as Km(mol) ≥ (10 x Vmax(mol)/Clearance) (data not included), and remained 
unchanged beyond this value. Thus a critical aspect of how the values may be related to 
each other depends on whether Km(mol) is larger or smaller than Vmax(mol)/Clearance. Due 
to the complexity of this relationship, it is difficult to explain why the switch (from one 
of logarithmic correlation to lack of it) takes place.  
It is important to note that we can use the relationships that we see in figs. 3 and 5 to 
examine if we have used the right substrate concentration in the experiments in 
accurately determine the Michaelis-Menten parameters. Note that in order to correctly 
determine the Michaelis-Menten parameters, substrate concentrations must be close to 
S(0), i.e. that substrate concentration in which the P-gp is at least 70% saturated. So how 
would the relationships that we have defined help? Let us assume that the maximum 
substrate concentration that we have used to “experimentally” determine the Michaelis-
Menten parameters (Vmax(EH) and Km(EH)) is S. We will need to know the drugs clearance 
rate, which can be easily measured. Knowing the clearance and Vmax(EH), we can 
determine Vmax(mol) using the relationship shown in fig. 3A. We can then determine Km(mol)  
from the relationship depicted in fig. 5B. Finally, the S(0) value from the relationship 
shown in fig.  5A. If S(0) ≤ S, we know that we have used substrate concentrations high 
enough to saturate P-gp, and hence our Vmax(EH) and Km(EH) (and hence Vmax(mol) and 
Km(mol)) values are appropriate. If not, we will have to use higher drug concentrations for 
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this purpose. The accurate determination of these values is important because they are a 
measure of the efficacy of the drug in vivo. 
In this study, we wanted to compare and contrast the steady state compartmental model 
from the minimal mass action model for all situations previously tested. Rather than 
question the physiological relevance of the various parameters, we wanted to test the 
strengths and weaknesses of both models. We conclude that both simulated models are 
equally robust in determining the Vmax and Km values, provided appropriate S(0) are used. 
While the “experimental” Vmax (Vmax(EH)) can be correlated to its respective molecular 
value (Vmax(mol)), the same is not possible for Km. We thus find that the original results in 
Bentz et al. (2005) hold for the extended range of clearances tested here. This, of course, 
is provided that the right S(0) values are used. One must keep in mind that while 
undertaking a steady state Michaelis-Menten study, S(0) values should be chosen such 
that a protein saturation of ≥ 70% is achieved. 
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Paper 2: Figure Legends 
 
Figure 1: Cartoon depicting drug efflux as described by the minimal mass action as 
well as the steady state Michaelis-Menten models. Passive permeability is shown on 
the left, active efflux as measured by the nonlinear steady state compartment model (SS) 
is shown in the center and active efflux as measured by the minimal comprehensive mass 
action model (MA) is shown on the right. While SS predicts the Michaelis-Menten 
parameters, Vmax and Km, MA predicts the elementary rate parameters and P-gp 
concentration that constitute the Michaelis-Menten parameters. CA, CB, and CC are the 
drug concentrations in the apical chamber, basolateral chamber and cytosol. CAO, CBO, 
and CPC are the drug concentrations in the apical membrane outer monolayer, basolateral 
membrane outer monolayer and the cytosolic side of the plasma membrane. 
 
Figure 2: Sample Eadie-Hofstee plot. Data for the plot was generated using the 
Michaelis-Menten model. Simulation conditions have been mentioned in the text. The 2 
hr time point to determine velocity, V. The Eadie-Hofstee plot of the data is curved, 
clearly indicating that only the highest substrate concentrations should be used to 
determine Vmax(EH) accurately. Lower substrate concentrations overestimate Vmax. Similar 
plots were obtained for data generated at the various conditions tested, and for both 
simulation models. 
 
Figure 3: Relation between Vmax(mol) and Vmax(EH) values. Data for the plot was 
generated using the Michaelis-Menten model. Closed markers indicate results obtained 
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by simulating efflux in the apical to basolateral (A>B) direction while open markers 
represent results obtained by simulating efflux in the basolateral to apical (B>A) direction.  
Drug clearance rates at which the efflux was simulated were, 10-4 (inverted triangles), 10-
3 (diamonds), 10-2 (upright triangles), 10-1 (circles) and 1 (squares) ml/min. Figure 3A 
indicated a logarithmic correlation between Vmax(mol) and Vmax(EH). Enclosed area 
indicates biologically relevant ranges as published by others (see text for details). Fig. 3B 
shows the correlation between Vmax(mol)/Vmax(EH) vs. drug clearance rates. With increasing 
drug clearance, Vmax(mol)/Vmax(EH) becomes larger as the Vmax(EH)  determined by 
simulation becomes smaller. At any given drug clearance rate, there is a 10–fold 
degeneracy in the Vmax(EH)(EH) determined. Similar results were obtained for data 
generated using the minimal mass action model. 
 
Figure 4: Relation between Km(mol) and Km(EH) values. Data for the plot was generated 
using the Michaelis-Menten model. Closed markers indicate results obtained by 
simulating efflux in the apical to basolateral (A>B) direction while open markers 
represent results obtained by simulating efflux in the basolateral to apical (B>A) direction.  
Drug clearance rates at which the efflux was simulated were, 10-4 (inverted triangles), 10-
3 (diamonds), 10-2 (upright triangles), 10-1 (circles) and 1 (squares) ml/min. There appears 
to be no correlation between the simulated Km(EH) and Km(mol) values (fig. 4A). In fact, for 
any “experimentally measured” Km(EH), Km(mol) could vary widely, depending on 
clearance (fig. 4B). At lower clearances it becomes more difficult to determine Km(mol) 
from the obtained Km(EH). Similar results were obtained for data generated using the 
minimal mass action model. 
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Figure 5: Correlation between Clearance, Vmax(mol), Km(mol), Vmax(EH), Km(EH) and S(0). 
Correlation between S(0)/Km(mol) and Vmax(mol)/(Clearance x Km(mol)) (Fig. 5A),  and 
between Vmax(EH)/(Clearance x Km(EH)) and Vmax(mol)/(Clearance x Km(mol)) (Fig. 5B). At 
Vmax(mol)/(Clearance x Km(mol)) lower than 10/ml, S(0)/Km(mol) remains unchanged and 
Vmax(EH)/(Clearance x Km(EH)) logarithmically increases. Above this value of Vmax(mol)-
/(Clearance x Km(mol)), S(0)/Km(mol) logarithmically increases, while Vmax(EH)/(Clearance x 
Km(EH)) remains unchanged.  Filled markers indicate trend for biologically relevant ranges 
as published by others (see text for details). 
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Figure 4: Paper 2, Figure 1: Cartoon depicting drug efflux as described by the minimal 
mass action as well as the steady state Michaelis-Menten models 
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Figure 5: Paper 2, Figure 2: Sample Eadie-Hofstee plot 
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Figure 6: Paper 2, Figure 3: Relation between Vmax(mol) and Vmax(EH) values 
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Figure 7: Paper 2, Figure 4: Relation between Km(mol) and Km(EH) values 
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Figure 8: Paper 2, Figure 5: Correlation between Clearance, Vmax(mol), Km(mol), Vmax(EH), 
Km(EH) and S(0) 
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Paper 2: Supplementary Material: Mass Balance Equations 
 
P-gp is generally assumed to follow the standard Michaelis-Menten reaction. This 
reaction takes place in the inner monolayer of the apical membrane: 
             
 
where T0 is the empty transporter, CPC is the concentration of the drug in the apical inner 
monolayer, T1 is the transporter bound by the substrate and CA is the substrate after efflux 
into the apical monolayer. In the steady-state model, we replace CPC with CC, the 
concentration of drug in the cellular compartment. Based on this reaction, the mass 
balance equations can be obtained for both models, as shown below. The values of the 
parameters, used in the simulations, have been indicated in parenthesis. 
 
Steady-State Model Analysis:  
Although the above reaction holds true for the steady state compartmental model, since 
this model does not distinguish between the cell cytoplasm and inner monolayer, drug 
concentration, CPC, is replaced by CC. Therefore mass balance equations in the apical 
compartment are: 
CAAB
Cm_SS
max_SS
AAAB
A
ap ).C.APCK
V
(.C.AP
dt
dC
.V +
+
+−=
   (1)  
where Vap (=1.5ml) is the volume of the apical compartment, CA (in M) and CC (in M) are 
the concentrations of drug in apical  and cytoplasmic chambers respectively, PAB is the 
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passive permeability coefficient across apical membrane (in nm/s; this is varied), AA 
(=2.26cm2) is the area of cellular apical membrane (note that PAB x AA is the drug 
clearance across the apical membrane), Vmax_SS is the maximal drug efflux velocity (in 
nmol/s) and Km_SS is the Michaelis-Menten constant (in M). 
 
In the cytoplasm we have: 
CBBAAAB
Cm_SS
max_SS
BBBAAAAB
C
cell ).C.AP.APCK
V
(.C.AP.C.AP
dt
dC.V ++
+
−+=
   (2) 
where Vcell (=11.56µl) is the volume of the apical compartment, PBA is the passive 
permeability coefficient across basolateral membrane (in nm/s; this is varied), AB 
(=2.26cm2) is the area of cellular basolateral membrane (note that PBA x AB is the drug 
clearance across the basolateral membrane) and CB (in M) is the concentrations of drug in 
basolateral chamber. 
  
Similarly, in the basolateral compartment we have: 
BBBACBBA
B
baso .C.AP.C.APdt
dC
.V −=   (3) 
where Vbaso (=2.5ml) is the volume of the basolateral compartment. 
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Minimal Mass Action Model Analysis:  
The confluent monolayer model takes into account all kinetically relevant parameters. 
We thus start with the elementary kinetic equations that define drug transport. At the 
apical side, we have: 
 12AOACAAB
A
A .T.kV)C(C.AP
dt
dC.V +−=   (4). where, AOAOAA .VKV.V += ,  
A
AO
AO C
CK =  
Here, VA is the volume of the aqueous apical chamber only (in ml) and VAO (0.5nl) is the 
volume of the entire outer apical monolayer. We assume AV  (the total volume on the 
apical chamber) to be equal to Vap and VA is calculated. KAO (= 70) is the equilibrium 
partition coefficient of the drug to the apical membrane outer monolayer. It is the ratio of 
the concentration of drug in the apical membrane outer monolayer (CAO, in M) to the 
concentration of drug in the aqueous apical chamber (CA, in M). T1 is the concentration 
of transporter bound with drug molecule, CC (in M) is the concentration of drug in 
cytoplasm, and k2 (= 5 s-1) is the drug efflux rate. The other parameters are as described in 
the steady-state model analysis. 
 
Mass balance equation in the cytoplasm yields: 
   
(5) 
where,  PCPCCC .VKV.V +=  , 
C
PC
PC C
C
K =  
1rAO0CPC1AOACAABCBBBA
C
C .T.kV.T.C.K.kV)C(C.AP)C(C.AP
dt
dC.V +−−−−=
 100
Here, VC is the volume of the cell cytoplasm only (in ml) and VPC (1nl) is the volume of 
the entire inner cell monolayer. We assume CV  (the total volume on the cytoplasmic 
chamber) to be equal to Vcell and VC is calculated. KPC (= 710) is the equilibrium partition 
coefficient of the drug to the plasma cytoplasmic monolayer. It is the ratio of the 
concentration of drug in the cytosolic side of plasma membrane (CPC, in M) to the 
concentration of drug in the cytoplasm (CC, in M). T0 is the concentration of transporter 
not bound with any drug. Note that T(0), the total concentration of P-gp (in M) is the sum 
of T0 and T1. This is calculated from the expected molecular Vmax(Vmax(mol)) and the 
assigned k2 value. Also, CB (in M) is the concentration of drug in aqueous basolateral 
chamber, k1 (= 3 x 109 M-1s-1) is the drug association rate and kr (in s-1) is the drug 
dissociation rate. kr is calculated from the expected molecular Km (Km(mol)).  We must 
point out over here that by considering the membrane partitioning coefficient to the 
plasma membrane, we take into account that the drug molecule is picked up from the 
inner monolayer. 
 
At the basolateral side we have: 
)C(C.AP
dt
dC.V cBBBABB −=     (6),   where BOBOBB .VKV.V +=  , 
B
BO
BO C
C
K =  
Here, VB is the volume of the aqueous basolateral chamber only (in ml) and VBO (0.5nl) is 
the volume of the entire outer basolateral monolayer. We assume BV  (the total volume 
on the basolateral chamber) to be equal to Vbaso and VB is calculated. KBO (= 110) is the 
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equilibrium partition coefficient of the drug to the basolateral membrane outer monolayer. 
It is the ratio of the concentration of drug in the basolateral membrane outer monolayer 
(CBO, in M) to the concentration of drug in the aqueous basolateral chamber (CB, in M). 
 
Finally, mass balance equation of the transporter yields: 
 (7)   and,    dt
dT
dt
dT 01
=     (8) 
 
At steady-state: 
 
 
Therefore 0CPC112r .T.C.Kk).Tk(k =+     (9) 
Now 10 TT(0)T −=  
Therefore )T.(T(0).C.Kk).Tk(k 1CPC112r −=+  or  
CPCm_MA
CPC
1 .CKK
.T(0).CK
T
+
=   (10), and  ).CK(K
.T(0)K
T
CPCm_MA
m_MA
0
+
=   (11; substituting 0T  for 
1T  in 9), where 
1
r2
m_MA k
kkK +=  
Km_MA is the Michaelis-Menten constant (in M). 
Therefore substituting for 0T  and 1T  in equations 4 and 5, we get: 
CPCm_MA
Cmax_MA
PCAOACAAB
A
A
.CKK
.CV
..KV)C(C.AP
dt
dC.V
+
+−=    (12) 
12r0CPC1
0 ).Tk(k.T.C.Kk
dt
dT
++−=
0
dt
dT0
=
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Vmax_MA is the maximal drug efflux velocity (in M/s) 
 
   
(13) 
 
A comparison of the compartmental and confluent monolayer models yields the 
following relations: 
AOmax_MAmax_SS .VVV = ;  
PC
m_MA
m_SS K
K
K =  
 
 
CPCm_MA
Cmax_MA
PCAOACAABCBBBA
C
C
.CKK
.CV
..KV)C(C.AP)C(C.AP
dt
dC
.V
+
−−−−=
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Paper 3: Abstract 
 
Microvilli are dynamic structures. They are known to undergo spontaneous contraction 
and elongation. This dynamicity affects the uptake and efflux of molecules by changing 
surface area available for passive permeation as well as expression of surface proteins, 
such as P-gp, that may be involved in transport. The aim of this study is to theoretically 
understand the effect of variable microvilli expression on efflux of amphipathic 
compounds, via simulations designed to resemble a confluent monolayer of cells. For our 
simulations, microvilli were assumed to be arranged in a hexagonal crystal lattice. The 
effluxed amphiphiles was allowed to randomly diffuse through the microvilli structure, 
thus allowing them to “escape” or get “reabsorbed”. We find that decreasing microvilli 
height and increasing distances of separation between adjacent microvilli increases the 
efflux of amphiphiles. Efflux of amphiphiles is the highest at the top of the microvilli and 
rapidly decreases as we move towards the microvilli base. We also find that there is a 
critical ratio of height to distance of separation between microvilli that influences the 
probability of escape. 
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Paper 3: Introduction 
 
The apical side of epithelial cells has a brush border domain composed of a large array of 
microvilli (Boyd et al., 1968; Boyd and Parsons, 1969; Mooseker, 1985). The presence of 
microvilli increases the apical surface area of cells, when compared to one without. This 
would directly affect passive transport through the cells. This may also be important for 
the expression of apical membrane proteins, such as P-glycoprotein (P-gp). A greater 
surface area on the apical side provides more area for (and thus possibly larger numbers 
of) proteins to be expressed. 
One may correlate microvilli expression to arrangements of long columns of lipids 
separated by an aqueous space. Drugs (which are essentially amphipathic) that are 
released from the bottom of the microvilli may be easily reabsorbed, rather than make it 
to the lumen. This becomes particularly important when attempting to study the kinetics 
of drug efflux through a confluent monolayer of epithelial cells, for example, efflux of 
amprenavir by P-gp expressed in MDCK II – hMDR1 cells (Tran et al., 2005; Acharya et 
al., 2006; Acharya et al., 2008). Drug molecules effluxed by P-gp expressed at the base of 
the microvilli may not reach the region of the apical chamber, where the sample is 
collected for measurement. Thus, the contribution of P-gp expressed at the base of the 
microvilli to drug efflux would not be observed. Tran et. al. (2005) refer to the P-gp 
concentration that directly contributes to the efflux process, i.e. P-gp that sends drug 
directly to the apical chamber, where it instantly equilibrates, as “efflux active” P-gp. 
They state that P-gp at the microvilli tips are the ones that may be regarded as “efflux 
active”. 
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An interesting corollary to the above situation is that changing the expression 
(length/density) of the microvilli would affect the density of P-gp expressed, besides 
affecting the passive transport (Tran et al., 2005). It is well known that microvilli are 
dynamic structures composed mainly of bundles of actin filaments (Mooseker, 1985). 
The presence of substances such as epidermal growth factors, as well as several 
drugs/toxins alter the expression of microvilli, in turn affecting transport (Lange et al., 
1990; Lange and Brandt, 1990b; White et al., 2000; Witowski et al., 2001; Tyska and 
Mooseker, 2002). 
Tran et. al. (2005) conducted experiments to determine the kinetics of drug efflux by P-
gp expressed in MDCK II – hMDR1 cells.  They determined P-gp expression, by fitting, 
to range from 3 – 320 per µm2, which they noted is ~10-20 fold lesser than that seen by 
Ambudkar et al. (1997) in NIH3T3 cells, by Western analysis. They hypothesize that 
their numbers would thus indicate only efflux active P-gp expressed. They correlate their 
hypothesis by comparing the surface area of the tips to the total surface area of the 
microvilli by crude estimations from the micrographs of Butor and Davoust (1992); they 
found that the tips comprise ~10% of the total microvilli surface. 
Interestingly, when Acharya et al. (2006) repeated these experiments, they found that 
their measurements of both, the passive permeability values and efflux active P-gp was 
double of that seen by Tran et al. (2005). They attribute the difference, in these 
determined quantities, between the two experiments, to changes in microvilli morphology. 
In this study, we computationally simulate varying conditions of microvilli expression 
seen on the apical membranes of epithelial cells. We vary the morphology by simulating 
different heights of and/or separation differences between microvilli. We want to 
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understand how changing morphologies can affect drug efflux. There are two main aims: 
(1) To determine if the majority of the efflux does occur from the tips of the microvilli, 
making only P-gp expressed at the tips “efflux active”, and, (2) To determine how much 
the morphology of the apical surface (i.e. the height of the microvilli and/or the density of 
microvilli expression) must change in order to see a measurable change in the number of 
molecules escaping. 
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Paper 3: Materials and Methods 
 
Our simulation set-up resembles a confluent cell monolayer grown on a porous 
membrane. This is common experimental system used to study drug efflux in vitro. Thus 
we aim to understand the effect of changing microvilli morphology on drug efflux in the 
same. 
All simulations for this study were done in MATLAB. Figure 1a is a cartoon depicting 
the transverse section of the brush border showing the cross-sectional geometry of the 
microvilli, that we will adopting for our simulations. This assumes a hexagonal lattice 
arrangement of the microvilli. This sort of arrangement has been observed in the 
epithelial cells of pigeons (Boyd et al., 1968), chickens (Stidwill and Burgess, 1986), and 
rat and human intestine (Mukherjee and Williams, 1967), and is hence relevant. The 
shaded portion shows the region within which efflux was simulated. Every other region is 
equivalent to this region. Figure 1b shows the reference planes/axes. The surface on 
which the base of the microvilli lie becomes the reference plane.  
We randomly divided the microvilli into several transverse sections from the tip to the 
base of the microvilli. An example of such a section is shown in figure 1b. Efflux from 
each transverse section is determined. The region closer to the microvilli tip (top 10% of 
the maximum height) had smaller sections since a preliminary study on a 2-D model 
showed that efflux was sensitive to the point of release in this region (data not shown). 
Efflux from the area between two microvilli is clubbed along with that from the bottom 
most transverse section.  
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To simulate efflux we “released” a molecule at a point (say A) closest to the adjacent 
microvilli (shown by filled circle in fig. 1a), 1nm away from the microvilli surface, at any 
one transverse section. The molecules were then allowed to randomly diffuse by a 
Brownian motion simulation similar to that described by Siegel and Langer (Siegel and 
Langer).  
In our simulations, we fix the current position of the molecule as the “origin” for this step. 
The reference planes for this step will be parallel to those shown in figure 1b, with the 
current position of the molecule as the origin. Thus, the “origin” will shift with each step.  
We first fix the step size at 1/3rd the distance from the molecule to its closest absorbing 
surface. We chose this value because we found that if the total distance to the nearest 
surface was assumed to be the step size, then 30% of the molecules got “absorbed” (see 
definition below) in the very first step. It is unlikely that a molecule would take a 1nm 
step close to the cell surface due to the high concentration of molecules present; 
Brownian motion would dictate a smaller step size. Thus by reducing the step size to 1/3rd 
(or ~ 30%) of the net distance to the absorbing surface, we abolished the possibility of a 
30% absorption in the very first step. We shall refer to the step size as “a”. 
Next, with the help of the random generator in MATLAB, we generate the azimuth angle 
(φ) and the elevation angle (θ). These angles are as defined by the spherical coordinate 
system. Note that 0≤φ≤2 π, and, -π/2≤θ≤ π /2. Again, we favored simulating the diffusion 
of the molecule with the help of a randomly generated elevation angle rather than an 
inclination angle as we found that by employing the concept of the inclination angle, we 
were favoring the molecule to move in either extreme of the z-direction, again something 
that we do not see in the real world.  
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Thus, in the next step, the distance that the molecule moves in each direction will be:  
In the x-direction: x = a.cos(θ).cos(φ);               (1) 
In the y-direction: y = a.cos(θ).sin(φ); and,               (2) 
In the z-direction: z = a.sin(θ)               (3) 
The net distance moved by the molecule can be calculated as √(x2 + y2 + z2). The 
molecule continues to diffuse till it either gets absorbed (i.e. comes within 0.1nm of any 
absorbing surface), or escapes (i.e., moves at least 0.5µm away from its closest absorbing 
surface. 
We repeat this process for 107 molecules released at the same point. We calculate the 
probability of escape at point A (PA) as: 
PA = Number of molecules that escape / Total number released           (4) 
We repeated this process by allowing molecules to escape from the point “furthest from 
adjacent microvilli” (marked by an “x” in figure 1a), at the same height. We found that 
the probability of escape from this point is similar to that as the “closest point” (no 
significant difference seen on performing a Student’s T-test, data not shown). Thus we 
assume that the probability of escape on each point along the circumference of the 
microvilli, at a particular height, will be the same, say PA.  
We assume that the height of each transverse section is small enough that the number of 
escapes decreases linearly from the top most point (say A) to the bottom most point (say 
B) of the section.  Then, for a particular transverse section (say the ith section) the 
probability of escape at any point (P, ith) within this section is: 
P, ith = (PA + PB) / 2                 (5) 
where PA and PB are determined from equation (4) 
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In order to compare how the probability of escape changes as we go down the microvilli, 
we repeated this process for each transverse section. 
In order to understand and compare the overall effects of changing microvilli dimension, 
we calculate the probability of efflux per unit area (E) of membrane at each pair of values 
of microvilli height and separation distances as:  
∑
∑
=
=
= n
1i
i
n
1i
i
th
A
).Ai(P,
E                 (6) 
where Ai is the area of the ith transverse section and n is the total number of transverse 
sections. Note that we were able to use this “weighted-average” method of summation 
only because we have shown that the probability of escape from each point in a given 
transverse section is the same. Also, in our case, ∑
=
n
1i
iA is the total surface area of the 
minimal region (shaded portion, fig. 1a) within which the efflux is simulated. 
We repeated this process a second time to confirm our results. The error bars in the 
figures represent the standard deviation of the two runs.  
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Paper 3: Results 
 
Examining the trend of escape of molecules as we go down the microvilli: Effect of 
varying microvilli dimensions: We wanted to compare the probability of “escape” for a 
molecule released from the tip vs. one released at the base of the microvilli. We define 
“escape” as the molecule being 0.5µm away from its closest absorbing surface 
(consequently, we define absorption as the molecule being within 0.1nm of the closest 
absorbing surface). The distance that a molecule has to be to “escape” or get “absorbed” 
is currently unknown. We feel that the distances that we have chosen are biologically 
relevant. These may be modified if the respective values are found to be different via 
experimental measurements. Escape probability is defined as the ratio of the number of 
molecules that escape to the total number effluxed.  
We looked at the effect of varying microvilli heights (0.5 µm, 1µm, 1.5µm and 3 µm) at a 
fixed separation distance (R). Separation distance is the distance between any two 
adjacent microvilli. Note that by increasing the separation distance, we can vary the 
density of microvilli expression. By looking at the trend at six different separation 
distances (0.1µm, 0.3µm, 1µm, 3µm, 10µm and, 20 µm), we were able to understand the 
effect of varying the separation distance (and hence the density of microvilli expression), 
at each microvilli height. Results for four different separation distances (0.1µm, 0.3µm, 
1µm and 3µm) have been shown (fig. 2). Trends at greater separation distances are 
similar to that seen at 3µm and hence not included. 
We find that the maximum probability of escape is from the microvilli tips, irrespective 
of the height or separation distance considered. This decreases as we go down the 
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microvilli. These trends are physiologically expected and thus this examination serves as 
an indication of the validity of our programming technique. However, we also find that 
this trend disappears at large separation distance. 
We find that when the microvilli are closest together (0.1µm), then there is a considerable 
decrease in the escape probability as we go down the microvilli, for microvilli at all 
heights. Increasing the separation distance significantly increases the probability of 
escape from the lower regions of the microvilli. When separation distance increases to 
3µm, then the probability of escape from each region of the microvilli is the same, 
irrespective of its height, i.e., the probability that a molecule effluxed at the base will 
escape is the same as that effluxed from the tip. 
On closer examination we find that as long as the height of the microvilli is greater than 
its separation distance, then the probability of escapes from the tips are always greater 
than any other region of the microvilli. However, when the separation distances equals 
(or becomes more than) the height, then the probability of escapes from all regions 
become the same. Varying the “absorption” or “escape” distance does not affect the trend 
seen (data not included). 
 
Effect of varying microvilli dimensions on the number of escapes per unit area of the 
membrane: In order to understand and compare the overall effects of changing microvilli 
dimension, it is important to relate each situation, described by a specific height and 
separation distance, by a common denominator. The number (or probability) of escapes 
per unit area is the simplest, yet complete parameter, that allows this comparison (see 
“Materials and Methods” to see how “Escapes per unit area” has been defined). An 
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expected trend is that as the height decreases and/or the separation distance increases, the 
number of escapes per unit area should increase. We see this trend with our simulation 
(fig 3A and 3B). We also find that when the separation distance is greater than 3µm, the 
number of escapes per unit area do not increase significantly, irrespective of the height of 
the microvilli.  
A complex combination of microvilli heights and separation distance influence the 
number of escapes (fig. 3C). We find that as long as the ratio of microvilli height to 
separation distance is less than or equal to 1 (i.e. height of microvilli ≤ separation 
distance), the number of escapes per unit area does not change. At ratios greater than one, 
the number of escapes logarithmically decreases. 
The ultimate goal of this simulation is to examine how much the height/separation 
distance should change in order to observe a measurable difference in the number of 
molecules escaping. If the number of escaping molecules changed by only 10%, we may 
not be able observe this through a microscope, due to a lack of sensitivity. A 50% change 
may be better detected. The effect of varying dimensions on the number of escapes is 
intricate. For example, for a microvilli with height = 0.5µm, increasing the separation 
distance from 0.1µm to 0.3µm (3 fold), increases the escape probability by 2.5 fold. 
However, increasing it from 1µm to 3 µm (again, 3 fold), only increases it by 1.5 fold 
(fig. 3A). Also, this effect varies with microvilli height. For 1.5µm tall microvilli, when 
the separation distance increases from 0.1µm to 0.3µm, the increase in escape probability 
increases more than 4 fold, while increasing the separation distance from 1µm to 3µm 
increases the escape probability by 2 fold (fig. 3A). Similarly, changing microvilli height 
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at lower separation distances has a much more profound effect than at higher separation 
distances (fig. 3B). 
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Paper 3: Discussion 
 
That microvilli are dynamic structures has been well established. The microvilli core is 
composed of actin filaments which undergo continuous retrograde translocation from the 
tips to the cell interior. While the actin filaments at the tips of the microvilli are 
disassembled and moved back towards the cell body, they are continuously balanced by 
the addition of actin monomers at the distal end, thereby maintaining microvilli length 
(Marshall, 2004). Microvilli have been shown to have a quick growth rate, a long a 
steady expression rate and a slow decay rate (Gorelik et al., 2003). An investigation of 
the epithelial cells of the human jejunum has also shown that the expression and density 
of the microvilli differs in different regions of a villous (Brown, 1962). 
The presence of several substances can alter the growth/stability of the microvilli. Several 
studies have been done in different cells to confirm this. For example studies have shown 
that exposure of rabbit jejunum cells to epidermal growth factor increases the brush 
border surface area (Hardin et al., 1993). Exposure of midgut epithelium to −δ endotoxin 
from Bacillus thuringiensis results in shorter microvilli being expressed (Lane et al., 
1989). 
A consequence of this dynamic microvilli morphology is that transport of substances 
and/or drugs can get affected. Increasing the surface area of the brush border epithelium 
increases passive transport. At the same time it increases the area in which proteins that 
may be involved in active efflux, may be expressed. One may note that if the density of 
microvilli expression increases, the chance of a drug effluxed at the base of the microvilli 
getting reabsorbed increases as well. This is because there will be less “free space” for 
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the molecule to move, before it encounters a membrane. This means that if one were able 
to take measurements of the drug being effluxed at the lumen, then most of the efflux will 
appear to be from the tips of the microvilli. There will be little to no contribution from the 
base. 
Our aim through this study was to determine how much the morphology of the microvilli 
should change in order to see a 50% change in efflux. We do this by simulating 
conditions resembling a confluent cell monolayer system, an experimental system often 
employed for in vitro studies. We decided to test for a 50% change so that it is easily 
measurable. Morphology can be changed by altering the height (length) and/or density of 
microvilli expression. Note that the easiest way to test the “change in density” is by 
increasing the distance of separation between adjacent microvilli. 
Our results clearly show that there is an intricate relationship between microvilli height, 
separation distance and the probability that an effluxed molecule will get to the apical 
chamber. We find that as long as the separation distance is greater than the height, then 
the escapes per unit area remains constant. When the height to separation distance ratio 
increases, the number of escapes per unit area dramatically falls (fig. 3C). This may be 
attributed to the fact that when tall microvilli are placed close to each other, then only the 
molecules effluxed from the tips of the microvilli make it to the apical chamber while 
others get reabsorbed. Thus there are a lesser number of escapes per unit area. 
Cross sectional views of the brush border of epithelial cells appear to show 
configurations in which the height of the microvilli is greater than the distance of 
separation (Brown, 1962; Hardin et al, 1993). Thus if one was to determine density of a 
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membrane protein through drug efflux kinetics, as done by Tran et al. (2005), then only 
the proteins at the tip of the microvilli will be accounted for. 
One may note from our results that per unit area only 15% of the emitted molecules 
escape (probability of escape per unit area ~ 0.15, fig. 3C). We attribute this to our 
stringent conditions of “absorption” and “escape” (see materials and methods). It is 
possible that the “absorption” and “escape distances” that we have chosen are very high 
for biological systems. We find that reducing these numbers increases the probability of 
escape (data not included). However, there are no studies that quantitate the “absorption” 
and “emission” distances. These may be changed when experimentally determined.  
It is important to point out that Richardson et al. (1973) performed a theoretical study to 
understand the effect of microvilli geometry on passive absorption. They did not look at 
the effect of geometry on efflux. It is also important to point out that the set-up that they 
had employed resembles a two dimensional model, rather than a three dimensional one.  
Thus there have been no suitable studies to understand the effects of varying microvilli 
morphology on diffusion through the cytosolic space between microvilli. This makes our 
study unique. Simulations give us an idea of what may happen under ideal conditions. 
Although toxins and growth factors do vary the heights of microvilli, there has been no 
indication as to whether this change is constant and/or uniform across all cells. Fewer 
studies corroborate uniformity in the density of microvilli expression.   Thus it becomes 
important to get an idea of what to expect under experimental conditions, before 
divulging into one. By comparing outputs from our simulation to experimental results, we 
may get a better idea of what the effect of the change in the morphology of the apical 
membrane of the cells to drug efflux may be like. In addition the range of heights and 
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separation distances that we have simulated include ones that are biologically relevant. 
Herein lies the importance of this study. 
 120
Paper 3: References 
 
1. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H and Bentz J (2008) 
Kinetic Identification of Membrane Transporters That Assist P-glycoprotein-
Mediated Transport of Digoxin and Loperamide through a Confluent Monolayer 
of MDCKII-hMDR1 Cells. Drug Metab. Dispos. 36:452-460. 
 
2. Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H and Bentz J (2006) P-
Glycoprotein (P-gp) Expressed in a Confluent Monolayer of hMDR1-MDCKII 
Cells Has More Than One Efflux Pathway with Cooperative Binding Sites. 
Biochemistry 45:15505-15519. 
 
3. Boyd CA and Parsons DS (1969) The fine structure of the microvilli of isolated 
brush borders of intestinal epithelial cells. J. Cell Biol. 41:646-651. 
 
4. Boyd JD, Hamilton WJ and Boyd CA (1968) The surface of the syncytium of the 
human chorionic villus. J. Anat. 102:553-563. 
 
5. Brown AL, Jr. (1962) Microvilli of the human jejunal epithelial cell. J. Cell Biol. 
12:623-627. 
 
6. Butor C and Davoust J (1992) Apical to basolateral surface area ratio and polarity 
of MDCK cells grown on different supports. Exp. Cell. Res. 203:115-127. 
 
7. Gorelik J, Shevchuk AI, Frolenkov GI, Diakonov IA, Lab MJ, Kros CJ, 
Richardson GP, Vodyanoy I, Edwards CR, Klenerman D and Korchev YE (2003) 
Dynamic assembly of surface structures in living cells. Proc. Natl. Acad. Sci. U S 
A 100:5819-5822. 
 
8. Hardin JA, Buret A, Meddings JB and Gall DG (1993) Effect of epidermal 
growth factor on enterocyte brush-border surface area. Am J Physiol Gastrointest 
Liver Physiol. 264:G312-318. 
 
9. Lane NJ, Harrison JB and Lee WM (1989) Changes in microvilli and Golgi-
associated membranes of lepidopteran cells induced by an insecticidally active 
bacterial δ-endotoxin. J. Cell. Sci. 93:337-347. 
 
10. Lange K and Brandt U (1990b) Restricted localization of the adipocyte/muscle 
glucose transporter species to a cell surface-derived vesicle fraction of 3T3-L1 
adipocytes. Inhibited lateral mobility of integral plasma membrane proteins in 
newly inserted membrane areas of differentiated 3T3-L1 cells. FEBS Lett. 
276:39-41. 
 
 121
11. Lange K, Brandt U and Zimmermann B (1990) Relationship between insulin 
stimulation and endogenous regulation of 2-deoxyglucose uptake in 3T3-L1 
adipocytes. J. Cell. Physiol. 142:1-14. 
 
12. Lown KS, Mayo RR, Leichtman AB, Hsiao H, Turgeon DK, Schmiedlin-Ren P, 
Brown MB, Guo W, Rossi SJ, Benet LZ and Watkins PB (1997) Role of intestinal 
P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of 
cyclosporine. Clin. Pharmacol. Ther. 62:248-260. 
 
13. Marshall WF (2004) Cellular length control systems. Ann. Rev. Cell Dev. Biol. 
20:677-693. 
 
14. Mooseker MS (1985) Organization, chemistry, and assembly of the cytoskeletal 
apparatus of the intestinal brush border. Ann. Rev. Cell Biol. 1:209-241. 
 
15. Mukherjee TM and Williams AW (1967) A Comparative Study of the 
Ultrastructure of Microvilli in the Epithelium of Small and Large Intestine of 
Mice. J. Cell Biol. 34:447-461. 
 
16. Richardson IW, Ličko V and Bartoli E (1973) The nature of passive flows 
through tightly folded membranes. J. Mem. Biol. 11:293-308. 
 
17. Siegel RA and Langer R (1986) A new Monte Carlo approach to diffusion in 
constricted  pores. J. Coll. Interface Sci. 109:426-440. 
 
18. Stidwill RP and Burgess DR (1986) Regulation of intestinal brush border 
microvillus length during development by the G- to F-actin ratio. Dev. Biol. 
114:381-388. 
 
19. Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H and Bentz J (2005) 
The elementary mass action rate constants of P-gp transport for a confluent 
monolayer of MDCKII-hMDR1 cells. Biophys. J. 88:715-738. 
 
20. Tyska MJ and Mooseker MS (2002) MYO1A (brush border myosin I) dynamics 
in the brush border of LLC-PK1-CL4 cells. Biophys. J. 82:1869-1883. 
 
21. White P, Doctor RB, Dahl RH and Chen J (2000) Coincident microvillar actin 
bundle disruption and perinuclear actin sequestration in anoxic proximal tubule. 
Am. J. Physiol. Renal Physiol. 278:F886-893. 
 
22. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, 
Frei U, Passlick-Deetjen J and Jorres A (2001) Prolonged exposure to glucose 
degradation products impairs viability and function of human peritoneal 
mesothelial cells. J. Am. Soc. Nephrol. 12:2434-2441. 
 
 
 122
Paper 3: Figure Legends 
 
Figure 1: Representations of arrangements and orientations employed for the 
simulations: Figure 1a is a cartoon representation of the hexagonal crystal lattice 
arrangement (transverse section) adopted to study the effects of the dynamicity of the 
microvilli on the probability of escape. R is the distance between adjacent microvilli. The 
shaded region represents the minimum region within which “efflux” needs to be 
simulated. Every other region is equivalent to this region. The filled circle indicates the 
point of release “closest” to the adjacent microvillus, while “x” indicates the point of 
release “farthest” from the adjacent microvilli. Figure 1b shows the transverse and 
vertical views with the axes of reference used in the simulations. An example transverse 
section is also shown.  
 
Figure 2: Effect of microvilli height on escape of effluxed drug: Examining the trend 
of varying 4 different heights on the probability of escape as we down the microvilli. We 
show this trend at 4 different separation distances: 0.1µm (fig. 2A), 0.3µm (fig. 2B), 1µm 
(fig. 2C), and 3µm (fig. 2D). The “adsorption distance” here is 0.1nm and the “escape 
distance” is 0.5µm. The highest probability of escape is at the tip of the microvilli, and 
decreases as we go down the microvilli. This trend disappears at large separation 
distances, i.e. while the trend is pronounced at a separation distance of 0.1µm, it is not at 
3µm. 
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Figure 3: Effect of varying microvilli morphology on the escapes per unit area: 
Effect of varying microvilli dimensions (separation distances (R) – Fig. 3A, and heights 
(Ht) – Fig. 3B) on the escapes per unit area of the membrane. For a microvilli at a given 
height, as the separation distance increases, the number of molecules escaping increases 
(Fig. 3A). However, the increase in the number of escapes is different for different 
heights. For microvilli at a specific distance of separation, as height increases, the number 
of escapes decreases (Fig. 3B). However, at large separation distances (≥0.3µm), the 
decrease is minimal. Closer examination shows that if Ht/R ≤ 1 then the escape 
probability does not change. For Ht/R > 1, escape probability decreases logarithmically 
(fig. 3C) 
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Figure 9: Paper 3, Figure 1: Representations of arrangements and orientations employed 
for the simulations 
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Figure 10: Paper 3, Figure 2: Effect of microvilli height on escape of effluxed drug 
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Figure 11: Paper 3, Figure 3: Effect of varying microvilli morphology on the escapes per 
unit area 
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Conclusion 
The importance of P-gp to the Absorption, Distribution, Metabolism and Excretion 
(ADME) of drugs is clear. It is able to extrude a variety of structurally unrelated drug 
molecules ranging from 300 to 4000 Daltons in mass. Its substrates include anticancer 
drugs, HIV protease inhibitors, analgesics, calcium channel blockers, cardiac glycosides, 
immunosuppressive agents, and antibiotics, to name a few (Sharom, 2007). 
P-gp is physiologically present in a number of cells, with the highest level of expression 
in barrier and excretory tissues. P-gp in the intestinal epithelium can extrude many drugs 
from the blood into the intestinal lumen thereby reducing the oral bioavailability of drugs. 
Presence of P-gp in the blood-brain barrier strongly reduces the presence of drugs in the 
organ. The failure of chemotherapy treatment to cure human cancers has also been 
attributed to the overexpression of P-gp, besides other transporters (Sharom, 2007) 
Blockade of P-gp by modulators can dramatically affect the systemic concentration of 
drugs by reducing elimination through the intestine, bile and urine. This phenomenon 
may be used to alter the pharmacological behavior of many drugs, to improve their 
delivery through biologically important barriers such as the blood brain barrier. 
The understanding of the structure and function of P-gp is vital to modulate the 
transporter. Only the minimal mass action model is capable of allowing an understanding 
of the structure-function relationship by predicting the elementary rate parameters. When 
Tran et al. developed the model, they were unable to successfully account for other 
proteins that may be involved in the drug transport pathway (Tran et al., 2004). In this 
study, we have been able to suitably modify the model to account for other possible 
proteins involved, as seen with the efflux of loperamide and digoxin. Not only that, we 
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have been able to successfully pinpoint the basis of the limitation of the minimal mass 
action model, thereby allowing effective extrapolation of the results obtained from in 
vitro fitting to in vivo conditions. We have also shown, via simulations, the effect of 
changing microvilli morphology to the elimination of drugs. Changing the morphology of 
the brush border can affect both passive transport and expression of membrane 
transporters, such as P-gp, which in turn affects the ADME of drugs. 
Now that we have a better understanding of the minimal mass action model, we may use 
this to understand the kinetics of efflux by other membrane proteins. Ones that 
immediately come to mind are Multidrug Resistance Protein 1 (MRP1, ABCC1) and the 
Breast Cancer Resistant Protein (BCRP, ABCG2) which are the other major drug efflux 
pumps expressed in human cancers. The model may also be employed to study ABC 
transporters in bacterial and yeast cells, especially those homologues that have been 
attributed to the development of drug resistant strains of harmful microbes such as 
Enterococcus faecalis, Mycobacterium tuberculosis, and, Pseudomonas aeruginosa. 
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